var title_f38_31_39408="Heller myotomy and fundoplication";
var content_f38_31_39408=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F52028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F52028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Heller myotomy and fundoplication",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is an intraoperative photograph of the anterior fundus of the stomach folded over the esophageal myotomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_31_39408=[""].join("\n");
var outline_f38_31_39408=null;
var title_f38_31_39409="Disassembled Gomco clamp";
var content_f38_31_39409=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Disassembled Gomco clamp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David G Weismiller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_31_39409=[""].join("\n");
var outline_f38_31_39409=null;
var title_f38_31_39410="Coronavirus EM";
var content_f38_31_39410=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Coronavirus electron micrograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Group of coronavirus particles, negatively stained with phosphotungstic acid (PTA). Some variation in size is seen, but shape is relatively uniform. Magnification 144,000x.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: McIntosh, K, Dees, JH, Becker, WB, et al. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proc Natl Acad Sci USA. 1967; 57(4):933. Copyright &copy; 1967 Kenneth McIntosh, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_31_39410=[""].join("\n");
var outline_f38_31_39410=null;
var title_f38_31_39411="Percutaneous aortic valvotomy";
var content_f38_31_39411=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Percutaneous aortic valvotomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/31/39411/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/31/39411/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/31/39411/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/31/39411/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/31/39411/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/31/39411/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/31/39411/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/31/39411/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic valve replacement is the mainstay of treatment of symptomatic aortic stenosis (AS). Aortic valve replacement offers substantial improvements in symptoms and life expectancy.",
"   </p>",
"   <p>",
"    However, aortic valve surgery entails substantial risks for some patients with severe comorbidities, and for some considered at &ldquo;extreme&rdquo; risk, surgery is not appropriate. In others, technical limitations, eg, porcelain aorta, may mean that surgery is not feasible. Percutaneous aortic valvotomy was developed as a less invasive means to treat AS but has important limitations. Subsequently developed catheter-based techniques for aortic valve implantation may provide an alternative method for treating AS in patients with unacceptably high estimated surgical risks. A multidisciplinary team approach is recommended in approaching patients with symptomatic AS. &nbsp;",
"   </p>",
"   <p>",
"    This topic will review percutaneous aortic valvuloplasty. Indications for aortic valve replacement, surgical aortic valve replacement, transcatheter aortic valve implantation (TAVI), estimating the risk of aortic valve surgery, and medical therapy of symptomatic AS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/8/31881?source=see_link\">",
"     \"Indications for valve replacement in aortic stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/37/11865?source=see_link\">",
"     \"Surgical valve replacement in aortic stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/29/34264?source=see_link\">",
"     \"Transcatheter aortic valve replacement\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/5/7252?source=see_link\">",
"     \"Estimating the mortality risk of valvular surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/43/41654?source=see_link\">",
"     \"Medical management of symptomatic aortic stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     AORTIC VALVOTOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous aortic balloon valvotomy is a procedure in which a balloon is placed across the stenotic aortic valve and inflated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39411/abstract/1\">",
"     1",
"    </a>",
"    ]. The aim is to relieve the stenosis by fracturing calcific deposits within the valve leaflets. Stretching of the annulus and separation of the calcified commissures also may contribute.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114805108\">",
"    <span class=\"h2\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of important limitations to the use of percutaneous valvotomy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite a moderate reduction in the transvalvular pressure gradient, which is often accompanied by an improvement in symptoms, the postprocedure valve area rarely exceeds 1.0 cm",
"      <sup>",
"       2",
"      </sup>",
"      , leaving the patient with persistent severe AS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39411/abstract/1,2\">",
"       1,2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In historical series, serious complications (stroke, aortic regurgitation, myocardial infarction, major access-related complications) occurred in approximately 10 to 20 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39411/abstract/1-5\">",
"       1-5",
"      </a>",
"      ]. In-hospital mortality rates were also about 10 to 20 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39411/abstract/3,6\">",
"       3,6",
"      </a>",
"      ]. However, anecdotal experience suggests that morbidity and mortality in contemporary practice is better than this due to improvements in balloons and technique.",
"     </li>",
"     <li>",
"      Restenosis and clinical deterioration occur in most cases within 6 to 12 months, and the long-term outcome resembles the natural history of untreated AS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39411/abstract/2,7\">",
"       2,7",
"      </a>",
"      ]. Repeat balloon valvotomy can be performed, but most patients fail within six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39411/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Possible indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the limitations observed with aortic valvotomy, the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    valve disease guidelines (with 2008 update) concluded that balloon valvotomy is",
"    <strong>",
"     not",
"    </strong>",
"    a substitute for valve replacement in adults, although selected young adults without valve calcification may represent an exception (",
"    <a class=\"graphic graphic_table graphicRef51270 \" href=\"mobipreview.htm?6/35/6716\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39411/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, balloon valvotomy is frequently used in children with valvular AS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7078?source=see_link\">",
"     \"Treatment of bicuspid aortic valve stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38345?source=see_link&amp;anchor=H18#H18\">",
"     \"Valvar aortic stenosis in children\", section on 'Balloon valvotomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the evidence is not well established, the guidelines noted two specific settings in adults in which balloon valvotomy might be reasonable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39411/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As a bridge to surgery in hemodynamically unstable patients who are at high risk for aortic valve replacement. However, mortality remains high in these patients after valvotomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39411/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/43/41654?source=see_link&amp;anchor=H13#H13\">",
"       \"Medical management of symptomatic aortic stenosis\", section on 'Critically ill patients awaiting valve replacement'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Use for palliation in patients with serious comorbid conditions that prevent performance of aortic valve replacement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, there are two other settings in which balloon valvotomy has been considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As a bridge to delivery in symptomatic pregnant women. Although there are case reports suggesting success, balloon valvotomy can induce aortic regurgitation even in experienced hands, the postdilation bicuspid aortic valve remains susceptible to infective endocarditis irrespective of its functional state, the ascending aorta still harbors an abnormal media, and recurrent stenosis is common within 6 to 12 months. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/25/27032?source=see_link\">",
"       \"Pregnancy in women with a bicuspid aortic valve\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients who require urgent noncardiac surgery. However, the",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      guidelines and others have concluded that most asymptomatic patients with severe AS can undergo urgent noncardiac surgery at relatively low risk with careful intraoperative and postoperative management, including monitoring of anesthesia and careful attention to fluid balance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39411/abstract/9,11,12\">",
"       9,11,12",
"      </a>",
"      ]. Balloon valvotomy was not recommended; aortic valve replacement should be considered if preoperative correction of AS is warranted [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39411/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/14/13544?source=see_link\">",
"       \"Noncardiac surgery in patients with aortic stenosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Use of balloon valvotomy as a bridge to transcatheter aortic valve implantation (TAVI) has been reported, but experience with this strategy is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39411/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recent improvements in both balloon technology and procedural technique may lead to a resurgence in the clinical application of balloon valvotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39411/abstract/14\">",
"     14",
"    </a>",
"    ]. A transseptal antegrade approach may decrease vascular complications compared to the conventional retrograde approach but is technically complex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39411/abstract/4\">",
"     4",
"    </a>",
"    ]. A preliminary report of aortic valvotomy using a low-profile compliant balloon that fits into an 8 or 9 Fr sheath suggests that such an approach may reduce vascular complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39411/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aortic valve replacement is the mainstay of treatment of symptomatic aortic stenosis (AS). Aortic valve replacement offers substantial improvements in symptoms and life expectancy.",
"     </li>",
"     <li>",
"      Limitations of percutaneous aortic balloon valvotomy include an approximately 10 to 20 percent risk of major procedural complications, generally transient hemodynamic and clinical benefit, and poor long-term outcomes similar to untreated severe AS. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A multidisciplinary team approach is recommended in approaching patients with symptomatic AS. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39411/abstract/1\">",
"      Nishimura RA, Holmes DR Jr, Reeder GS. Percutaneous balloon valvuloplasty. Mayo Clin Proc 1990; 65:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39411/abstract/2\">",
"      Lieberman EB, Bashore TM, Hermiller JB, et al. Balloon aortic valvuloplasty in adults: failure of procedure to improve long-term survival. J Am Coll Cardiol 1995; 26:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39411/abstract/3\">",
"      Percutaneous balloon aortic valvuloplasty. Acute and 30-day follow-up results in 674 patients from the NHLBI Balloon Valvuloplasty Registry. Circulation 1991; 84:2383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39411/abstract/4\">",
"      Klein A, Lee K, Gera A, et al. Long-term mortality, cause of death, and temporal trends in complications after percutaneous aortic balloon valvuloplasty for calcific aortic stenosis. J Interv Cardiol 2006; 19:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39411/abstract/5\">",
"      Nietlispach F, Wijesinghe N, Wood D, et al. Current balloon-expandable transcatheter heart valve and delivery systems. Catheter Cardiovasc Interv 2010; 75:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39411/abstract/6\">",
"      Cubeddu RJ, Jneid H, Don CW, et al. Retrograde versus antegrade percutaneous aortic balloon valvuloplasty: immediate, short- and long-term outcome at 2 years. Catheter Cardiovasc Interv 2009; 74:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39411/abstract/7\">",
"      Litvack F, Jakubowski AT, Buchbinder NA, Eigler N. Lack of sustained clinical improvement in an elderly population after percutaneous aortic valvuloplasty. Am J Cardiol 1988; 62:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39411/abstract/8\">",
"      Ferguson JJ, Garza RA. Efficacy of multiple balloon aortic valvuloplasty procedures. The Mansfield Scientific Aortic Valvuloplasty Registry Investigators. J Am Coll Cardiol 1991; 17:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39411/abstract/9\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39411/abstract/10\">",
"      Moreno PR, Jang IK, Newell JB, et al. The role of percutaneous aortic balloon valvuloplasty in patients with cardiogenic shock and critical aortic stenosis. J Am Coll Cardiol 1994; 23:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39411/abstract/11\">",
"      Christ M, Sharkova Y, Geldner G, Maisch B. Preoperative and perioperative care for patients with suspected or established aortic stenosis facing noncardiac surgery. Chest 2005; 128:2944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39411/abstract/12\">",
"      Torsher LC, Shub C, Rettke SR, Brown DL. Risk of patients with severe aortic stenosis undergoing noncardiac surgery. Am J Cardiol 1998; 81:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39411/abstract/13\">",
"      Kapadia SR, Goel SS, Svensson L, et al. Characterization and outcome of patients with severe symptomatic aortic stenosis referred for percutaneous aortic valve replacement. J Thorac Cardiovasc Surg 2009; 137:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39411/abstract/14\">",
"      Hara H, Pedersen WR, Ladich E, et al. Percutaneous balloon aortic valvuloplasty revisited: time for a renaissance? Circulation 2007; 115:e334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39411/abstract/15\">",
"      Yamen E, Daniels DV, Van H, et al. Use of a low-profile, compliant balloon for percutaneous aortic valvuloplasty. Catheter Cardiovasc Interv 2010; 75:794.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8141 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-5D5ABCD1C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_31_39411=[""].join("\n");
var outline_f38_31_39411=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      AORTIC VALVOTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H114805108\">",
"      Limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Possible indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8141\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8141|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/35/6716\" title=\"table 1\">",
"      BAV AS adolescents young adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/5/7252?source=related_link\">",
"      Estimating the mortality risk of valvular surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/8/31881?source=related_link\">",
"      Indications for valve replacement in aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/43/41654?source=related_link\">",
"      Medical management of symptomatic aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/14/13544?source=related_link\">",
"      Noncardiac surgery in patients with aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/25/27032?source=related_link\">",
"      Pregnancy in women with a bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/37/11865?source=related_link\">",
"      Surgical valve replacement in aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/29/34264?source=related_link\">",
"      Transcatheter aortic valve replacement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7078?source=related_link\">",
"      Treatment of bicuspid aortic valve stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38345?source=related_link\">",
"      Valvar aortic stenosis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_31_39412="Ulipristal: Drug information";
var content_f38_31_39412=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ulipristal: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/36/22084?source=see_link\">",
"    see \"Ulipristal: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10519685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      ella&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10519806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Contraceptive;",
"     </li>",
"     <li>",
"      Progestin Receptor Modulator",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F10579713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Emergency contraception:",
"     </b>",
"     Oral: One tablet (30 mg) as soon as possible, but within 120 hours (5 days) of unprotected intercourse or contraceptive failure",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F10579712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not for use prior to menarche.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F10579714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not indicated for use in postmenopausal women.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F11285145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as acetate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ella&reg;: 30 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F10579629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10579748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with or without food at anytime during menstrual cycle. If vomiting occurs within 3 hours of administration, consider repeating dose. Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10519808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Emergency contraception following unprotected intercourse or possible contraceptive failure",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F10579628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ulipristal may be confused with ursodiol",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F10579637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (18% to 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Menstruation occurring &ge;7 days later than expected (19%), dysmenorrhea (7% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abdominal pain (8% to 15%), nausea (12% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (6%), dizziness (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Intermenstrual bleeding (9%), menstruation occurring &ge;7 days earlier than expected (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports: Acne",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10579633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Known or suspected pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10579634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bleeding irregularities: Menstrual bleeding patterns may be altered (cycle length may be delayed or shortened by a few days), but returns to normal in subsequent cycles.  Intermenstrual bleeding (spotting) has also been observed. The possibility of pregnancy should be considered if menstruation is delayed for &gt;7 days of the expected menstrual period.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ectopic pregnancy: A history of ectopic pregnancy is not a contraindication to use in emergency contraception. The possibility of ectopic pregnancy should be considered in patients with abdominal pain after administration of ulipristal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Safety and efficacy have not been established for use in hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Safety and efficacy have not been established for use in renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: Not for use prior to menarche.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Postmenopausal women: Not indicated for use in postmenopausal women.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Not intended for routine contraception. Repeated use within the same menstrual cycle is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Fertility: Oral tablet: Barrier contraception is recommended immediately following emergency contraception and throughout the same menstrual cycle; efficacy of hormonal contraception may be decreased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; HIV infection protection: Does not protect against HIV infection or other sexually-transmitted diseases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pregnancy: Exclude pregnancy prior to therapy via history, physical exam or pregnancy testing; not indicated for terminating an existing pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F11304727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10579643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: St John's wort (an enzyme inducer) may decrease serum levels of ulipristal.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F10579630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10579631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Embryofetal loss was observed following administration of ulipristal to pregnant rats and rabbits during the period of organogenesis at doses that were",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     and",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     the human dose (based on BSA), respectively. Teratogenic effects were not observed in surviving fetuses. Pregnancy terminations were also observed in pregnant monkeys following administration of ulipristal during the first trimester in doses ~3 times the human dose (based on BSA). Exclude pregnancy prior to therapy; not indicated for terminating an existing pregnancy. A rapid return of fertility is expected following use for emergency contraception; routine contraceptive measures should be initiated or continued following use to ensure ongoing prevention of pregnancy. Barrier contraception is recommended immediately following emergency contraception and throughout the same menstrual cycle; efficacy of hormonal contraceptives may be decreased.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F10579632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F10579747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ella Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (1): $42.90",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10579750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Evaluate for pregnancy or ectopic pregnancy if menses is delayed for &ge;1 week following emergency contraception, or if lower abdominal pain (3-5 weeks after administration) or persistent irregular bleeding develops.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ella (IL, SG);",
"     </li>",
"     <li>",
"      ellaOne (AT, BE, CZ, DK, EE, FR, GB, HN, KP, NL, NO, PL, PT, SE);",
"     </li>",
"     <li>",
"      Esmya (GB)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10579744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevents progestin from binding to the progesterone receptor. Ulipristal postpones follicular rupture when administered prior to ovulation, thereby inhibiting or delaying ovulation. May also alter the normal endometrium, impairing implantation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10579706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Ulipristal: &gt;94% to plasma proteins including albumin, alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein, and high-density lipoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via CYP3A4; forms monodemethylated metabolite (active) and inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Ulipristal: ~32 hours; Monodemethylated metabolite: ~27 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, serum: 1 hour (ulipristal and monodemethylated metabolite)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Fine P, Math&eacute; H, Ginde S, et al, &ldquo;Ulipristal Acetate Taken 48-120 Hours After Intercourse for Emergency Contraception,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2010, 115(2 Pt 1):257-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39412/abstract-text/20093897/pubmed\" id=\"20093897\" target=\"_blank\">",
"        20093897",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Glasier AF, Cameron ST, Fine PM, et al, &ldquo;Ulipristal Acetate Versus Levonorgestrel for Emergency Contraception: A Randomised Non-Inferiority Trial And Meta-Analysis,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2010, 375(9714):555-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39412/abstract-text/20116841/pubmed\" id=\"20116841\" target=\"_blank\">",
"        20116841",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15626 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-CCFD8525CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_31_39412=[""].join("\n");
var outline_f38_31_39412=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10519685\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10519806\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10579713\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10579712\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10579714\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11285145\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10579629\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10579748\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10519808\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10579628\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10579637\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10579633\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10579634\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300192\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11304727\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10579643\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10579630\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10579631\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10579632\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10579747\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322864\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10579750\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390247\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10579744\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10579706\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15626\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15626|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/36/22084?source=related_link\">",
"      Ulipristal: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_31_39413="Nutrition label fiber PI";
var content_f38_31_39413=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F51585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F51585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Nutrition label",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 451px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is an example of a nutrition label. To know how much fiber is in a food, look at the line that reads \"dietary fiber.\" This product has 3 grams of fiber in each serving.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_31_39413=[""].join("\n");
var outline_f38_31_39413=null;
var title_f38_31_39414="Pleural effusion radiograph";
var content_f38_31_39414=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86360%7EPEDS%2F86361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86360%7EPEDS%2F86361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Right-sided pneumonia with pleural effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 375px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dwight A Powell, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Computed tomography: Left-sided pneumonia with pleural effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dwight A Powell, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_31_39414=[""].join("\n");
var outline_f38_31_39414=null;
var title_f38_31_39415="Evaluation of sore throat in children";
var content_f38_31_39415=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of sore throat in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/31/39415/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/31/39415/contributors\">",
"     Gary R Fleisher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/31/39415/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/31/39415/contributors\">",
"     George A Woodward, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/31/39415/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/31/39415/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/31/39415/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/31/39415/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sore throat refers to any painful sensation localized to the pharynx or surrounding anatomy. The developmental ability of young children to identify and define their symptoms varies and the physician must pay careful attention to the patient and the caretaker in order to clarify the exact nature of the complaint.",
"   </p>",
"   <p>",
"    Sore throat can be the symptom of a disease process that does not directly affect the pharynx. Occasionally, young patients with dysphagia that results from disease in the area of the esophagus or with difficulty swallowing because of a neuromuscular disorder may verbalize these sensations as a sore throat or their symptoms may be interpreted by a caretaker as a sore throat.",
"   </p>",
"   <p>",
"    This topic will review conditions that can cause the symptom of sore throat. The discussion will include pertinent features of the history and physical examination and an algorithmic approach to common and life threatening conditions. The approach to the child with infectious pharyngitis is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/28/41417?source=see_link\">",
"     \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Life-threatening conditions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Epiglottitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of epiglottitis, a well-appreciated cause of life-threatening upper airway infection, has declined significantly since the introduction of vaccination against Haemophilus influenzae type b [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39415/abstract/1\">",
"     1",
"    </a>",
"    ]. This disease manifests with a toxic appearance, high fever, stridor, and drooling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39415/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Sore throat occurs in many cases, but is only rarely the primary complaint. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4826?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Retropharyngeal abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retropharyngeal abscesses can cause sore throat and usually occur in children less than four years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39415/abstract/4\">",
"     4",
"    </a>",
"    ]. Other complaints include neck pain and fever. There may be difficulty swallowing and respiratory distress. The posterior location of the abscess makes it difficult to visualize on physical examination. Imaging is often required to confirm the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43992?source=see_link\">",
"     \"Retropharyngeal infections in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Lateral pharyngeal abscesses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lateral pharyngeal abscesses produce symptoms similar to retropharyngeal infections but occur less often [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39415/abstract/5\">",
"     5",
"    </a>",
"    ]. High fever is common. Other signs include trismus and swelling below the mandible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Peritonsillar abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;A peritonsillar abscess may complicate a previously diagnosed infectious pharyngitis or may be the initial source of a child's discomfort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39415/abstract/6\">",
"     6",
"    </a>",
"    ]. This disease is most common in older children and adolescents. The diagnosis is evident from visual inspection, augmented occasionally by careful palpation. The abscess produces a bulge in the posterior aspect of the soft palate, deviates the uvula to the contralateral side of the pharynx, and has a fluctuant quality on palpation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43992?source=see_link\">",
"     \"Retropharyngeal infections in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Infectious mononucleosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infectious mononucleosis can rarely cause airway obstruction from severe tonsillar hypertrophy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Diphtheria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diphtheria is a life-threatening but seldom encountered cause of infectious pharyngitis, characterized by a thick pharyngeal membrane and marked cervical adenopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/38/29287?source=see_link\">",
"     \"Epidemiology, pathophysiology and clinical manifestations of diphtheria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Lemierre's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;This unusual infection is caused by Fusobacterium necrophorum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39415/abstract/7\">",
"     7",
"    </a>",
"    ] or mixed anaerobic flora and is associated with jugular venous thrombophlebitis and the dissemination of infection by septic emboli. It should be considered in the ill-appearing patient with severe pharyngitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39415/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43992?source=see_link&amp;anchor=H20#H20\">",
"     \"Retropharyngeal infections in children\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Common conditions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Viral pharyngitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection is the most common cause of sore throat and the etiologic agents are usually respiratory viruses, including adenoviruses, coxsackie A viruses, influenza, or parainfluenza virus (",
"    <a class=\"graphic graphic_table graphicRef60174 \" href=\"mobipreview.htm?2/1/2077\">",
"     table 1",
"    </a>",
"    ). Some of these viruses produce easily identifiable syndromes, including herpangina or hand, foot, and mouth disease (coxsackie virus) and pharyngoconjunctival fever (adenovirus). Herpangina is common in infants and young children and decreases in frequency as age increases. Herpes simplex virus usually causes stomatitis (discussed below). However, it may cause pharyngitis in the immunocompromised child, and rarely in the immunocompetent child. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34585?source=see_link\">",
"     \"Clinical manifestations and diagnosis of enterovirus and parechovirus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39257?source=see_link\">",
"     \"Epidemiology and clinical manifestations of adenovirus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Streptococcal pharyngitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral etiologies are closely followed in frequency by group A streptococcus (Streptococcus pyogenes), which is the most frequent bacterial cause of infectious pharyngitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39415/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In the winter months during streptococcal outbreaks, as many as 30 percent of episodes of pharyngitis may be caused by S. pyogenes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/28/41417?source=see_link&amp;anchor=H3#H3\">",
"     \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\", section on 'Bacteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Infectious mononucleosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only other common infectious agent in pharyngitis is the Epstein-Barr virus (EBV), which causes infectious mononucleosis and affects adolescents most frequently. Rarely, infectious mononucleosis can cause life threatening airway obstruction from tonsillar hypertrophy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/55/14202?source=see_link\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An additional consideration in adolescents with an infectious mononucleosis-like syndrome is human immunodeficiency virus (HIV). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/2/13353?source=see_link\">",
"     \"The stages and natural history of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other conditions",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unusual infections &ndash; Other organisms produce pharyngitis only rarely; these include Neisseria gonorrhoeae, Corynebacterium diphtheriae, Francisella tularensis, and anaerobic bacteria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      N. gonorrhoeae may cause inflammation and exudate but more often remains quiescent and is diagnosed only by culture [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39415/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/35/26166?source=see_link\">",
"       \"Diagnosis of gonococcal infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oropharyngeal tularemia is rare and should be entertained only in endemic areas among children who have an exudative pharyngitis that cannot be categorized by standard diagnostic testing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      persists despite antibiotic therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14166?source=see_link\">",
"       \"Epidemiology, microbiology, and pathogenesis of tularemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30888?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of tularemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other organisms, including group C and G streptococci, Arcanobacterium hemolyticum, Mycoplasma pneumoniae, and Chlamydophila (Chlamydia) pneumoniae [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39415/abstract/13\">",
"       13",
"      </a>",
"      ], have been implicated as agents of pharyngitis in adolescents and adults, but in childhood their roles remain unproven and their frequency is unknown.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Irritative pharyngitis &ndash; Drying of the pharynx may irritate the mucosa, leading to a complaint of sore throat. This condition occurs most commonly during the winter months, particularly after a night's sleep in a house with forced hot-air heating.",
"     </li>",
"     <li>",
"      Foreign body &ndash; Occasionally, a foreign object such as a fish bone may become embedded in the pharynx. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/33/2585?source=see_link&amp;anchor=H3#H3\">",
"       \"Airway foreign bodies in children\", section on 'Presentation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Herpetic stomatitis &ndash; Stomatitis caused by herpes simplex usually is confined to the anterior buccal mucosa but may extend to the tonsillar pillars. In these more extensive cases, the child may complain of a sore throat. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=see_link\">",
"       \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Systemic inflammatory conditions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Kawasaki disease is characterized by high fever along with at least four of the five following findings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39415/abstract/14\">",
"       14",
"      </a>",
"      ]: conjunctivitis, mucositis, peripheral erythema",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      edema, truncal rash, cervical adenopathy. Kawasaki disease is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/19/11575?source=see_link\">",
"       \"Kawasaki disease: Epidemiology and etiology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stevens-Johnson syndrome is a disease of unknown etiology, but presumed to be immune mediated, which is characterized by vesicular and ulcerative lesions of the mucosa, including the pharynx, genitalia, and conjunctivae. Additionally, children with this condition may have a diffuse rash, often consisting of target lesions or vesicles and bullae. Usually self-limited, occasional cases may lead to dehydration or progress to involve the pulmonary system. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=see_link\">",
"       \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Behcet's syndrome is a more chronic systemic inflammatory disease that may involve the oral cavity. It is uncommon in children. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/18/298?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Periodic fever with aphthous stomatitis, pharyngitis and adenitis (PFAPA syndrome) is a cyclical inflammatory disease of unknown etiology. Episodes occur primarily in school age children approximately every four weeks. Mean duration of illness ranges from four to eight years. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/11/8377?source=see_link&amp;anchor=H4#H4\">",
"       \"Periodic fever with aphthous stomatitis, pharyngitis and adenitis (PFAPA syndrome)\", section on 'Clinical manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/11/8377?source=see_link&amp;anchor=H15#H15\">",
"       \"Periodic fever with aphthous stomatitis, pharyngitis and adenitis (PFAPA syndrome)\", section on 'Natural history'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chemical exposure &ndash; Certain ingestions, such as paraquat and various alkalis, may cause a chemical injury to the mucosa of the pharynx. Usually these findings occur in the setting of a known ingestion and are accompanied by lesions of the oral mucosa. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/23/4473?source=see_link\">",
"       \"Caustic esophageal injury in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Referred pain &ndash; Occasionally, pain from inflammation of extrapharyngeal structures is described as arising in the pharynx. Examples include dental abscesses, cervical adenitis, and otitis media.",
"     </li>",
"     <li>",
"      Psychogenic pharyngitis &ndash; Some children who complain of a sore throat have no organic explanation for their complaint identified after a thorough history and physical examination and a throat culture. In these cases, the physician should consider the possibility of anxiety, at times associated with frequent or difficult (globus hystericus) swallowing. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/19/21814?source=see_link\">",
"       \"Globus sensation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Immunosuppressed host &ndash; Immunosuppressed hosts may develop pharyngitis from any of the previously discussed causes. In addition, these patients exhibit a particular susceptibility to infections with fungal organisms, such as Candida albicans. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31481?source=see_link&amp;anchor=H3#H3\">",
"       \"Overview of Candida infections in children\", section on 'Oropharyngeal candidiasis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Key historical variables that may assist in the diagnosis of a specific cause of sore throat include respiratory distress, fever, fatigue, and the rapidity of the onset of symptoms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sore throat and respiratory distress &ndash; The combination of sore throat and respiratory distress suggests conditions in or near the pharynx that are producing an obstruction, including epiglottitis, retropharyngeal or lateral pharyngeal abscess, peritonsillar abscess, massive tonsillar hypertrophy secondary to infectious mononucleosis, and rarely diphtheria.",
"     </li>",
"     <li>",
"      Fever &ndash; Fever points to one of the many infectious causes (",
"      <a class=\"graphic graphic_table graphicRef60174 \" href=\"mobipreview.htm?2/1/2077\">",
"       table 1",
"      </a>",
"      ) but may also occur with inflammatory conditions.",
"     </li>",
"     <li>",
"      Fatigue &ndash; Fatigue, particularly when prolonged, characterizes infectious mononucleosis.",
"     </li>",
"     <li>",
"      Abrupt onset &ndash; Among the diseases causing pharyngitis, epiglottitis has a particularly abrupt onset, in a matter of hours, while infectious mononucleosis manifests over a period of days or weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other factors in the history that may be important in selected cases include immunocompromising conditions, immunizations, travel, and sexual activity. The patient with a compromised immune system is susceptible to a number of infections, including Candida albicans. Diphtheria rarely merits consideration, except in unimmunized children and those from underdeveloped nations. With a history of oral sexual activity, pharyngeal gonorrhea may be a concern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;To a large degree, the evaluation of the child with a complaint of sore throat hinges on a careful physical examination, particularly of the pharynx.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stridor, drooling, or respiratory distress indicate airway obstruction and may be present in the occasional patients with conditions such as epiglottitis or retropharyngeal abscess.",
"     </li>",
"     <li>",
"      An inflamed eardrum suggests pain from a non-oropharyngeal site and swelling around a tooth indicates a likely dental abscess.",
"     </li>",
"     <li>",
"      The appearance of vesicles on the buccal mucosa anterior to the tonsillar pillars points to a herpetic stomatitis or noninfectious syndromes, such as Behcet's or Stevens-Johnson syndrome (erythema multiforme). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=see_link\">",
"       \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/18/298?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Generalized inflammation of the oral mucosa, in a persistently febrile child, suggests Kawasaki disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/19/11575?source=see_link\">",
"       \"Kawasaki disease: Epidemiology and etiology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A foreign body, such as a fish bone, may uncommonly become lodged in the mucosal folds of the tonsils or pharynx; usually, the history suggests the diagnosis, but an unanticipated sighting may occur in the younger child.",
"     </li>",
"     <li>",
"      Significant asymmetry of the tonsils indicates a peritonsillar cellulitis or, if extensive, an abscess. Clinically, the diagnosis of an abscess is reserved for the tonsil that protrudes beyond the midline, causing the uvula to deviate to the uninvolved side.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infectious pharyngitis evokes a spectrum of inflammatory responses that range from minimal injection of the mucosa to beefy erythema with exudation and edema formation. Erythema and exudate, which may be secondary to either viral or bacterial pathogens, will be present in the majority of patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/28/41417?source=see_link&amp;anchor=H2#H2\">",
"     \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\", section on 'Etiology and clinical clues'",
"    </a>",
"    .) Several specific findings are useful in pinpointing an etiologic agent.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viral pharyngitis that results from Coxsackie virus will be self-evident in a few cases on the basis of vesicular formation in the posterior pharynx alone (herpangina) or in combination with involvement of the extremities (hand, foot, and mouth disease). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34585?source=see_link\">",
"       \"Clinical manifestations and diagnosis of enterovirus and parechovirus infections\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=see_link\">",
"       \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The typical appearance of streptococcal pharyngitis includes fever, exudative pharyngitis, palatal petechiae, and swollen anterior cervical lymph nodes. Strategies for improving the clinical diagnosis of streptococcal pharyngitis, including a scoring system, are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/28/41417?source=see_link&amp;anchor=H2#H2\">",
"       \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\", section on 'Etiology and clinical clues'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diphtheria causes a particularly thick exudate (diphtheritic membrane), often in association with tremendous enlargement of the cervical lymph nodes (\"bull neck\"). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/38/29287?source=see_link\">",
"       \"Epidemiology, pathophysiology and clinical manifestations of diphtheria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In infectious mononucleosis, the examination may show large, mildly tender posterior cervical lymph nodes, diffuse lymphadenopathy outside the cervical region,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hepatosplenomegaly. Although some young children with EBV infection do not always develop this typical pattern of signs and symptoms, many will have fever, pharyngitis, and cervical lymphadenopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39415/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/55/14202?source=see_link\">",
"       \"Clinical manifestations and treatment of Epstein-Barr virus infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ANCILLARY STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history and physical examination will often suffice for diagnosis. Ancillary studies that may be useful include testing for streptococcal disease by antigen detection or culture and a heterophile test and white blood cell count with differential for infectious mononucleosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39415/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/28/41417?source=see_link&amp;anchor=H16#H16\">",
"     \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\", section on 'Diagnostic approach'",
"    </a>",
"    .) Children can have symptomatic primary EBV infection without the production of heterophile antibodies and EBV specific serology may be necessary to make the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39415/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/55/14202?source=see_link\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A soft-tissue radiographic examination of the lateral neck may be useful in the child who is ill appearing, has significant difficulty swallowing, or who will not move his neck. An abnormal epiglottis and a retropharyngeal abscess can be identified on this view (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67878 \" href=\"mobipreview.htm?22/26/22958\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In order to diagnose a retropharyngeal abscess, the radiograph should be a true lateral, and the child must keep the neck in extension during inspiration to avoid a false thickening of the retropharyngeal space. Findings consistent with a retropharyngeal abscess include a prevertebral space that is increased in depth compared with the anteroposterior measurement of the adjacent vertebral body, or a retropharyngeal space that is greater than 7 mm at C2 or 14 mm at C6 (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63233 \" href=\"mobipreview.htm?23/20/23887\">",
"     image 2",
"    </a>",
"    ). Another method for interpreting the width of the prevertebral space is that it should normally measure no more than half the thickness of the vertebral body from C1-C4, or the full thickness from C5-C7. If the diagnosis remains uncertain despite adequate radiographs, a computed tomography (CT) scan should be obtained. A CT scan will confirm the diagnosis of a lateral abscess (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51505 \" href=\"mobipreview.htm?11/46/12015\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    If radiographs are normal and a lateral pharyngeal abscess is suspected on the basis of torticollis or asymmetrically enlarged anterior cervical lymph nodes, then a CT scan is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ALGORITHMIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tendency of most clinicians is to assume that one of the common organisms is the cause of pharyngitis in the child with a sore throat. Before settling on infectious pharyngitis, however, the clinician should first at least briefly consider several more serious disorders (",
"    <a class=\"graphic graphic_algorithm graphicRef72946 \" href=\"mobipreview.htm?24/60/25551\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Acutely ill patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions that have immediate life-threatening potential include epiglottitis, retropharyngeal and lateral pharyngeal abscesses, peritonsillar abscess, severe tonsillar hypertrophy (usually as an exaggerated manifestation of infectious mononucleosis), diphtheria, and Lemierre's syndrome.",
"   </p>",
"   <p>",
"    Generally, stridor and signs of respiratory distress accompany the complaint of sore throat in epiglottitis and retropharyngeal abscess. Drooling occurs commonly in children with these two conditions. Patients with epiglottitis, peritonsillar abscess, or severe infectious tonsillar hypertrophy often experience a change in their voice. In cases of epiglottitis or retropharyngeal abscess that are not clinically obvious, a lateral neck radiograph, obtained under appropriate supervision, is confirmatory.",
"   </p>",
"   <p>",
"    Peritonsillar abscess and tonsillar hypertrophy are diagnosed by visual examination of the pharynx. Diphtheria, which produces a thick pharyngeal exudate and markedly enlarged cervical lymph nodes, is rarely a consideration except in unimmunized children, particularly those from underdeveloped nations.",
"   </p>",
"   <p>",
"    Lemierre's syndrome is a complication of mixed anaerobic pharyngeal infection leading to sepsis. The child appears toxic, has high fever, neck pain, often has asymmetrically enlarged anterior cervical lymph nodes, and may be hypotensive.",
"   </p>",
"   <p>",
"    The next phase of the evaluation of the child with a complaint of sore throat hinges on a careful physical examination, particularly of the pharynx. The appearance of vesicles on the buccal mucosa anterior to the tonsillar pillars points to a herpetic stomatitis or noninfectious syndromes, such as Behcet's or Stevens-Johnson syndrome (erythema multiforme), and generalized inflammation of the oral mucosa in a persistently febrile child suggests Kawasaki disease.",
"   </p>",
"   <p>",
"    Uncommonly, a small, pointed foreign body, perhaps a fish bone, becomes lodged in the mucosal folds of the tonsils or pharynx; usually, the history suggests the diagnosis, but an unanticipated sighting may occur in the younger child. Significant asymmetry of the tonsils indicates a peritonsillar cellulitis or, if extensive, an abscess. Clinically, the diagnosis of an abscess is reserved for the tonsil that protrudes beyond the midline, causing the uvula to deviate to the uninvolved side.",
"   </p>",
"   <p>",
"    A pharynx that is not inflamed suggests a source of referred pain or irritative pharyngitis. Sources of referred pain (otitis media, dental abscess, and cervical adenitis) usually are identified during the examination. Irritative pharyngitis, seen most commonly during the winter among older children who live in homes with forced hot-air heating, produces minimal or no pharyngeal inflammation. It often is transient, appearing on arising and resolving by midday.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Suspected infectious pharyngitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who do not have one of the life threatening conditions discussed above and do not have another easily identifiable cause of sore throat (eg, foreign body) are likely to have infectious pharyngitis.",
"   </p>",
"   <p>",
"    Infectious pharyngitis evokes a spectrum of inflammatory responses that range from minimal injection of the mucosa to beefy erythema with exudation and edema formation (",
"    <a class=\"graphic graphic_algorithm graphicRef64820 \" href=\"mobipreview.htm?30/37/31327\">",
"     algorithm 2",
"    </a>",
"    ). The three relatively common causes are streptococci, respiratory viruses, and infectious mononucleosis. In a few cases, a viral pharyngitis that results from Coxsackie virus infection will be evident on the basis of vesicular formation in the posterior pharynx alone (herpangina) or in combination with involvement of the extremities (hand, foot, and mouth disease). Such patients require only symptomatic therapy.",
"   </p>",
"   <p>",
"    For patients without pharyngeal vesicles who have significant symptoms with pharyngeal erythema",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    exudate, it is prudent to obtain a rapid test for group A streptococcus, followed by a throat culture if the rapid test is negative. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/28/41417?source=see_link&amp;anchor=H16#H16\">",
"     \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\", section on 'Diagnostic approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the rare child with an unusual history, the physician must pursue diagnoses such as gonococcal pharyngitis (sexual abuse, oral sex) or diphtheria (immigration from an underdeveloped country, lack of immunization). If no diagnosis has yet been made in a child who has persistent sore throat and fever, infectious mononucleosis merits consideration even in the absence of lymphadenopathy and splenomegaly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/55/14202?source=see_link\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/26/28066?source=see_link\">",
"       \"Patient information: Sore throat in children (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/34/8738?source=see_link\">",
"       \"Patient information: Strep throat in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/22/3427?source=see_link\">",
"       \"Patient information: Sore throat in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the evaluation of sore throat is summarized in the algorithms (",
"    <a class=\"graphic graphic_algorithm graphicRef72946 \" href=\"mobipreview.htm?24/60/25551\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef64820 \" href=\"mobipreview.htm?30/37/31327\">",
"     algorithm 2",
"    </a>",
"    ). The table summarizes the causes of sore throat (",
"    <a class=\"graphic graphic_table graphicRef60174 \" href=\"mobipreview.htm?2/1/2077\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39415/abstract/1\">",
"      Shah RK, Roberson DW, Jones DT. Epiglottitis in the Hemophilus influenzae type B vaccine era: changing trends. Laryngoscope 2004; 114:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39415/abstract/2\">",
"      Johnson GK, Sullivan JL, Bishop LA. Acute epiglottitis. Review of 55 cases and suggested protocol. Arch Otolaryngol 1974; 100:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39415/abstract/3\">",
"      Mauro RD, Poole SR, Lockhart CH. Differentiation of epiglottitis from laryngotracheitis in the child with stridor. Am J Dis Child 1988; 142:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39415/abstract/4\">",
"      Craig FW, Schunk JE. Retropharyngeal abscess in children: clinical presentation, utility of imaging, and current management. Pediatrics 2003; 111:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39415/abstract/5\">",
"      Nagy M, Pizzuto M, Backstrom J, Brodsky L. Deep neck infections in children: a new approach to diagnosis and treatment. Laryngoscope 1997; 107:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39415/abstract/6\">",
"      Brodsky L, Sobie SR, Korwin D, Stanievich JF. A clinical prospective study of peritonsillar abscess in children. Laryngoscope 1988; 98:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39415/abstract/7\">",
"      Centor RM. Expand the pharyngitis paradigm for adolescents and young adults. Ann Intern Med 2009; 151:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39415/abstract/8\">",
"      Goldenberg NA, Knapp-Clevenger R, Hays T, Manco-Johnson MJ. Lemierre's and Lemierre's-like syndromes in children: survival and thromboembolic outcomes. Pediatrics 2005; 116:e543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39415/abstract/9\">",
"      Ramirez S, Hild TG, Rudolph CN, et al. Increased diagnosis of Lemierre syndrome and other Fusobacterium necrophorum infections at a Children's Hospital. Pediatrics 2003; 112:e380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39415/abstract/10\">",
"      Breese BB. A simple scorecard for the tentative diagnosis of streptococcal pharyngitis. Am J Dis Child 1977; 131:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39415/abstract/11\">",
"      Wald ER, Green MD, Schwartz B, Barbadora K. A streptococcal score card revisited. Pediatr Emerg Care 1998; 14:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39415/abstract/12\">",
"      Wiesner PJ, Tronca E, Bonin P, et al. Clinical spectrum of pharyngeal gonococcal infection. N Engl J Med 1973; 288:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39415/abstract/13\">",
"      Komaroff AL, Aronson MD, Pass TM, et al. Serologic evidence of chlamydial and mycoplasmal pharyngitis in adults. Science 1983; 222:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39415/abstract/14\">",
"      Barron KS. Kawasaki disease in children. Curr Opin Rheumatol 1998; 10:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39415/abstract/15\">",
"      Horwitz CA, Henle W, Henle G, et al. Clinical and laboratory evaluation of infants and children with Epstein-Barr virus-induced infectious mononucleosis: report of 32 patients (aged 10-48 months). Blood 1981; 57:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39415/abstract/16\">",
"      Fleisher GR, Paradise JE, Lennette ET. Leukocyte response in childhood infectious mononucleosis. Caused by Epstein-Barr virus. Am J Dis Child 1981; 135:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39415/abstract/17\">",
"      Fleisher G, Lennette ET, Henle G, Henle W. Incidence of heterophil antibody responses in children with infectious mononucleosis. J Pediatr 1979; 94:723.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6457 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-8D13A6BE0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_31_39415=[""].join("\n");
var outline_f38_31_39415=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Life-threatening conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Epiglottitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Retropharyngeal abscess",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Lateral pharyngeal abscesses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Peritonsillar abscess",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Infectious mononucleosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Diphtheria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Lemierre's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Common conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Viral pharyngitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Streptococcal pharyngitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Infectious mononucleosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ANCILLARY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ALGORITHMIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Acutely ill patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Suspected infectious pharyngitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6457\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6457|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?24/60/25551\" title=\"algorithm 1\">",
"      Pediatric sore throat initial approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?30/37/31327\" title=\"algorithm 2\">",
"      Suspected infectious pharyngitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6457|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?22/26/22958\" title=\"diagnostic image 1\">",
"      Epiglottitis x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?23/20/23887\" title=\"diagnostic image 2\">",
"      Retropharyngeal abscess plain radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?11/46/12015\" title=\"diagnostic image 3\">",
"      Retropharyngeal abscess CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6457|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/1/2077\" title=\"table 1\">",
"      Etiology sore throat",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/33/2585?source=related_link\">",
"      Airway foreign bodies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/28/41417?source=related_link\">",
"      Approach to diagnosis of acute infectious pharyngitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/23/4473?source=related_link\">",
"      Caustic esophageal injury in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/18/298?source=related_link\">",
"      Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34585?source=related_link\">",
"      Clinical manifestations and diagnosis of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/55/14202?source=related_link\">",
"      Clinical manifestations and treatment of Epstein-Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30888?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of tularemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/35/26166?source=related_link\">",
"      Diagnosis of gonococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39257?source=related_link\">",
"      Epidemiology and clinical manifestations of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14166?source=related_link\">",
"      Epidemiology, microbiology, and pathogenesis of tularemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/38/29287?source=related_link\">",
"      Epidemiology, pathophysiology and clinical manifestations of diphtheria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4826?source=related_link\">",
"      Epiglottitis (supraglottitis): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/19/21814?source=related_link\">",
"      Globus sensation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/19/11575?source=related_link\">",
"      Kawasaki disease: Epidemiology and etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31481?source=related_link\">",
"      Overview of Candida infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/22/3427?source=related_link\">",
"      Patient information: Sore throat in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/26/28066?source=related_link\">",
"      Patient information: Sore throat in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/34/8738?source=related_link\">",
"      Patient information: Strep throat in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/11/8377?source=related_link\">",
"      Periodic fever with aphthous stomatitis, pharyngitis and adenitis (PFAPA syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43992?source=related_link\">",
"      Retropharyngeal infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/2/13353?source=related_link\">",
"      The stages and natural history of HIV infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_31_39416="School action plan B";
var content_f38_31_39416=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71869&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71869&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    School asthma action plan (continued)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 702px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_31_39416=[""].join("\n");
var outline_f38_31_39416=null;
var title_f38_31_39417="Metoprolol: Drug information";
var content_f38_31_39417=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Metoprolol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/28/25030?source=see_link\">",
"    see \"Metoprolol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/11/15544?source=see_link\">",
"    see \"Metoprolol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F195796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lopressor&reg;;",
"     </li>",
"     <li>",
"      Toprol-XL&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F195797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Metoprolol (Type L&reg;);",
"     </li>",
"     <li>",
"      Apo-Metoprolol SR&reg;;",
"     </li>",
"     <li>",
"      Apo-Metoprolol&reg;;",
"     </li>",
"     <li>",
"      Ava-Metoprolol;",
"     </li>",
"     <li>",
"      Ava-Metoprolol (Type L);",
"     </li>",
"     <li>",
"      Betaloc&reg;;",
"     </li>",
"     <li>",
"      Dom-Metoprolol-B;",
"     </li>",
"     <li>",
"      Dom-Metoprolol-L;",
"     </li>",
"     <li>",
"      JAMP-Metoprolol-L;",
"     </li>",
"     <li>",
"      Lopresor SR&reg;;",
"     </li>",
"     <li>",
"      Lopresor&reg;;",
"     </li>",
"     <li>",
"      Metoprolol Tartrate Injection, USP;",
"     </li>",
"     <li>",
"      Metoprolol-25;",
"     </li>",
"     <li>",
"      Metoprolol-L;",
"     </li>",
"     <li>",
"      Mylan-Metoprolol (Type L);",
"     </li>",
"     <li>",
"      Nu-Metop;",
"     </li>",
"     <li>",
"      PMS-Metoprolol-B;",
"     </li>",
"     <li>",
"      PMS-Metoprolol-L;",
"     </li>",
"     <li>",
"      Riva-Metoprolol-L;",
"     </li>",
"     <li>",
"      Sandoz-Metoprolol (Type L);",
"     </li>",
"     <li>",
"      Sandoz-Metoprolol SR;",
"     </li>",
"     <li>",
"      Teva-Metoprolol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F195848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antianginal Agent;",
"     </li>",
"     <li>",
"      Beta-Blocker, Beta-1 Selective",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F195801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Angina:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Immediate release:",
"     </i>",
"     Initial: 50 mg twice daily; usual dosage range: 50-200 mg twice daily; maximum: 400 mg/day; increase dose at weekly intervals to desired effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Extended release:",
"     </i>",
"     Initial: 100 mg/day (maximum: 400 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Atrial fibrillation/flutter (ventricular rate control), supraventricular tachycardia (SVT) (acute treatment; unlabeled use; Antman, 2004; Fuster, 2006; Neumar, 2010):",
"     </b>",
"     I.V.: 2.5-5 mg every 2-5 minutes (maximum total dose: 15 mg over a 10-15 minute period).",
"     <b>",
"      Note:",
"     </b>",
"     Initiate cautiously in patients with concomitant heart failure; avoid in patients with decompensated heart failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance: Oral (immediate release): 25-100 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Heart failure:",
"     </b>",
"     Oral:",
"     <i>",
"      Extended release:",
"     </i>",
"     Initial: 25 mg once daily (reduce to 12.5 mg once daily in NYHA class higher than class II); may double dosage every 2 weeks as tolerated (target dose: 200 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Immediate release:",
"     </i>",
"     Initial: 50 mg twice daily; effective dosage range: 100-450 mg/day in 2-3 divided doses; increase dose at weekly intervals to desired effect; maximum: 450 mg/day; usual dosage range (JNC 7): 50-100 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Extended release:",
"     </i>",
"     Initial: 25-100 mg once daily; increase doses at weekly (or longer) intervals to desired effect; maximum: 400 mg/day; usual dosage range (JNC 7): 50-100 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension/ventricular rate control:",
"     </b>",
"     I.V. (in patients having nonfunctioning GI tract): Initial: 1.25-5 mg every 6-12 hours; titrate initial dose to response. Initially, low doses may be appropriate to establish response; however, although not routine, up to 15 mg administered as frequently as every 3 hours has been employed in patients with refractory tachycardia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Myocardial infarction:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acute: I.V.: 5 mg every 2 minutes for 3 doses in early treatment of myocardial infarction; thereafter, give 50 mg orally every 6 hours beginning 15 minutes after last I.V. dose and continue for 48 hours; then administer a maintenance dose of 100 mg twice daily.",
"     <b>",
"      Note:",
"     </b>",
"     Do not initiate this regimen in those with signs of heart failure, a low output state, increased risk of cardiogenic shock, or other contraindications (eg, second- or third-degree heart block). If initial I.V. dosing is not tolerated, may give 25-50 mg orally (depending on degree of intolerance) every 6 hours beginning 15 minutes after the last I.V. dose or as soon as clinical condition permits.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Secondary prevention (unlabeled use; Olsson, 1992): Oral: Immediate release: 25-100 mg twice daily; optimize dose based on heart rate and blood pressure; continue indefinitely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Thyrotoxicosis (unlabeled use):",
"     </b>",
"     Oral: Immediate release: 25-50 mg every 6 hours; may also consider administering extended release formulation (Bahn, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note: Switching dosage forms:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      When switching from immediate release metoprolol to extended release,",
"     </i>",
"     the same total daily dose of metoprolol should be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      When switching between oral and intravenous dosage forms,",
"     </i>",
"     equivalent beta-blocking effect is achieved when doses in a 2.5:1 (Oral:I.V.) ratio is used. For example, if the patient is receiving an oral dose of 25 mg twice daily (50 mg/day), this would translate to 5 mg I.V. every 6 hours; consider reducing initial I.V. dose to evaluate patient response.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F195823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/11/15544?source=see_link\">",
"      see \"Metoprolol: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Immediate release tablet:",
"     </i>",
"     Children: 1-17 years (National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, 2004): Initial: 1-2 mg/kg/day; maximum 6 mg/kg/day (&le;200 mg/day); administer in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Extended release tablet:",
"     </i>",
"     Children &ge;6 years: Initial: 1 mg/kg once daily (maximum initial dose: 50 mg/day). Adjust dose based on patient response (maximum: 2 mg/kg/day or 200 mg/day)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F195802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. In the management of hypertension, consider lower initial doses and titrate to response (Aronow, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5660888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F195804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No specific dosage adjustment provided in manufacturer&rsquo;s labeling; however a reduced dose may be necessary; titrate to response.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F195767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as tartrate: 1 mg/mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lopressor&reg;: 1 mg/mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as tartrate [preservative free]: 1 mg/mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as tartrate: 25 mg, 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lopressor&reg;: 50 mg, 100 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as succinate: 25 mg [expressed as mg equivalent to tartrate], 50 mg [expressed as mg equivalent to tartrate], 100 mg [expressed as mg equivalent to tartrate], 200 mg [expressed as mg equivalent to tartrate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Toprol-XL&reg;: 25 mg, 50 mg, 100 mg, 200 mg [scored; expressed as mg equivalent to tartrate]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F195752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F195771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Extended release tablets may be divided in half; do not crush or chew. Administer immediate release tablets with or immediately following food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: I.V. dose is much smaller than oral dose. When administered acutely for cardiac treatment, monitor ECG and blood pressure; may administer by rapid infusion (I.V. push) over 1 minute. May also be administered by slow infusion (ie, 5-10 mg of metoprolol in 50 mL of fluid) over ~30-60 minutes during less urgent situations (eg, substitution for oral metoprolol).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F195855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Abciximab, alteplase, amiodarone, argatroban, bivalirudin, eptifibatide, meperidine, milrinone, morphine, procainamide.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, lidocaine, nitroglycerin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Diltiazem, furosemide, heparin, nesiritide, nitroprusside.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F195770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of angina pectoris, hypertension, or hemodynamically-stable acute myocardial infarction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Extended release: Treatment of angina pectoris or hypertension; to reduce mortality/hospitalization in patients with heart failure (stable NYHA Class II or III) already receiving ACE inhibitors, diuretics, and/or digoxin",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F195844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of ventricular arrhythmias, atrial ectopy; migraine prophylaxis, essential tremor; prevention of reinfarction and sudden death after myocardial infarction; prevention and treatment of atrial fibrillation and atrial flutter; multifocal atrial tachycardia; symptomatic treatment of hypertrophic obstructive cardiomyopathy; management of thyrotoxicosis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F195857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lopressor&reg; may be confused with Lyrica&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Metoprolol may be confused with metaproterenol, metoclopramide, metolazone, misoprostol",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Metoprolol succinate may be confused with metoprolol tartrate",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Toprol-XL&reg; may be confused with TEGretol&reg;, TEGretol&reg;-XR, Topamax&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Significant differences exist between oral and I.V. dosing. Use caution when converting from one route of administration to another.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F195846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency may not be defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension (1% to 27%), bradycardia (2% to 16%), first-degree heart block (P-R interval &ge;0.26 sec; 5%), arterial insufficiency (usually Raynaud type; 1%), chest pain (1%), CHF (1%), edema (peripheral; 1%), palpitation (1%), syncope (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness (2% to 10%), fatigue (1% to 10%), depression (5%), confusion, hallucinations, headache, insomnia, memory loss (short-term), nightmares, sleep disturbances, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatology: Pruritus (5%), rash (5%), photosensitivity, psoriasis exacerbated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido decreased, Peyronie&rsquo;s disease (&lt;1%), diabetes exacerbated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (5%), constipation (1%), flatulence (1%), gastrointestinal pain (1%), heartburn (1%), nausea (1%), xerostomia (1%), vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Claudication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Musculoskeletal pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea (1% to 3%), bronchospasm (1%), wheezing (1%), rhinitis, shortness of breath",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Cold extremities (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Agranulocytosis, alkaline phosphatase increased, alopecia (reversible), anxiety, arthralgia, arthritis, cardiogenic shock, diaphoresis increased, dry eyes, gangrene, hepatitis, HDL decreased, impotence, jaundice, lactate dehydrogenase increased, nervousness, paresthesia, retroperitoneal fibrosis, second-degree heart block, taste disturbance, third-degree heart block, thrombocytopenia, transaminases increased, triglycerides increased, urticaria, vomiting, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Other events reported with beta-blockers: Catatonia, emotional lability, fever, hypersensitivity reactions, laryngospasm, nonthrombocytopenic purpura, respiratory distress, thrombocytopenic purpura",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F195775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypersensitivity to metoprolol, any component of the formulation, or other beta-blockers",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Additional contraindications are formulation and/or indication specific.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Immediate release tablets/injectable formulation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Hypertension and angina:",
"     </i>",
"     Sinus bradycardia; second- and third-degree heart block; cardiogenic shock; overt heart failure; sick sinus syndrome (except in patients with a functioning artificial pacemaker); severe peripheral arterial disease; pheochromocytoma (without alpha blockade)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Myocardial infarction:",
"     </i>",
"     Severe sinus bradycardia (heart rate &lt;45 beats/minute);  significant first-degree heart block (P-R interval &ge;0.24 seconds); second- and third-degree heart block; systolic blood pressure &lt;100 mm Hg; moderate-to-severe cardiac failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Extended release tablet:",
"     </b>",
"     Severe bradycardia, second- and third degree heart block; cardiogenic shock; decompensated heart failure; sick sinus syndrome (except in patients with a functioning artificial pacemaker)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F195756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse events:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated allergen challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Atrioventricular (AV) block: Metoprolol commonly produces mild first-degree heart block (P-R interval &gt;0.2-0.24 sec). Metoprolol may also produce severe first- (P-R interval &ge;0.26 sec), second-, or third-degree heart block. Patients with acute myocardial infarction (especially right ventricular myocardial infarction) have a high risk of developing heart block of varying degrees. If severe heart block occurs, metoprolol should be discontinued and measures to increase heart rate should be employed. Use of concomitant therapy that may also cause heart block or bradycardia (eg, calcium channel blockers, cardiac glycosides) should be done with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Symptomatic hypotension may occur with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; however, metoprolol, with B",
"     <sub>",
"      1",
"     </sub>",
"     selectivity, has been used cautiously with close monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction abnormality: Consider pre-existing conditions such as sick sinus syndrome before initiating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Use with caution in patients with compensated heart failure; monitor for a worsening of heart failure (only the extended release product is indicated for use in heart failure).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral vascular disease (PVD) and Raynaud's disease: Can precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud's disease. Use with caution and monitor for progression of arterial obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pheochromocytoma (untreated): Adequate alpha-blockade is required prior to use of any beta-blocker.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psoriasis: Beta-blocker use has been associated with induction or exacerbation of psoriasis, but cause and effect have not been firmly established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disease: Use with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If hyperthyroidism is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm. Alterations in thyroid function tests may be observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Bradycardia may be observed more frequently in elderly patients (&gt;65 years of age); dosage reductions may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extended release: Use care in compensated heart failure and monitor closely for a worsening of the condition. May need to increase diuretics and wait until clinically stable to advance dose to target.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abrupt withdrawal:",
"     <b>",
"      [U.S. Boxed Warning]: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered over 1-2 weeks to avoid acute tachycardia, hypertension, and/or ischemia.",
"     </b>",
"     Severe exacerbation of angina, ventricular arrhythmias, and myocardial infarction (MI) have been reported following abrupt withdrawal of beta-blocker therapy. Temporary but prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Major surgery: Although perioperative beta-blocker therapy is recommended prior to elective surgery in selected patients, use of high-dose extended release metoprolol in patients na&iuml;ve to beta-blocker therapy undergoing noncardiac surgery has been associated with bradycardia, hypotension, stroke, and death. Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F195842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (minor), CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F195761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors: May increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: May diminish the antihypertensive effect of Metoprolol. Mirabegron may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; FluvoxaMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Theophylline Derivatives.  Management: Monitor for reduced theophylline efficacy during concomitant use with any beta-blocker.  Beta-1 selective agents are less likely to antagonize theophylline than nonselective agents, but selectivity may be lost at higher doses.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F195792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food increases absorption. Metoprolol serum levels may be increased if taken with food. Management: Take immediate release tartrate tablets with food; succinate can be taken with or without food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Some herbal medications may worsen hypertension (eg, licorice); others may increase the antihypertensive effect of metoprolol (eg, shepherd's purse). Management: Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), gotu kola, licorice, and yohimbe. Avoid black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, and shepherd's purse.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F195763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F195778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal studies; therefore, the manufacturer classifies metoprolol as pregnancy category C. Metoprolol crosses the placenta and can be detected in cord blood, amniotic fluid, and the serum of newborn infants. In a cohort study, an increased risk of cardiovascular defects was observed following maternal use of beta-blockers during pregnancy. Intrauterine growth restriction (IUGR), small placentas, as well as fetal/neonatal bradycardia, hypoglycemia, and/or respiratory depression have been observed following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to beta-blockers as a class. Adequate facilities for monitoring infants at birth should be available. Untreated chronic maternal hypertension and pre-eclampsia are also associated with adverse events in the fetus, infant, and mother. The clearance of metoprolol is increased and serum concentrations and AUC of metoprolol are decreased during pregnancy. Metoprolol has been evaluated for the treatment of hypertension in pregnancy, but other agents may be more appropriate for use.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F195808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F195779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of metoprolol can be detected in breast milk. The manufacturer recommends that caution be exercised when administering metoprolol to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F195780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immediate release tablets should be taken with food. Extended release tablets may be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F195777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Lopressor Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (5 mL): $23.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Metoprolol Tartrate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (5 mL): $1.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Metoprolol Succinate ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $105.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $105.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $158.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $251.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Toprol XL Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $143.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $143.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $215.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $343.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lopressor Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $216.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $325.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Metoprolol Tartrate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $24.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $55.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $80.10",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F195765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute cardiac treatment: Monitor ECG and blood pressure with I.V. administration; heart rate and blood pressure with oral administration. I.V. use in a nonemergency situation: Necessary monitoring for surgical patients who are unable to take oral beta-blockers (because of prolonged ileus) has not been defined. Some institutions require monitoring of baseline and postinfusion heart rate and blood pressure when a patient's response to beta-blockade has not been characterized (ie, the patient's initial dose or following a change in dose). Consult individual institutional policies and procedures.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F195781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Angimet (PH);",
"     </li>",
"     <li>",
"      Beloc (AR, AT, CO, DE);",
"     </li>",
"     <li>",
"      Beloc Duriles (AT);",
"     </li>",
"     <li>",
"      Beloc Zok (CH);",
"     </li>",
"     <li>",
"      Beloken (IE);",
"     </li>",
"     <li>",
"      Betaloc (AU, CL, CO, GB, HK, HN, HU, IN, KP, MY, PH, PL, RU, TH);",
"     </li>",
"     <li>",
"      Betaloc CR (NZ);",
"     </li>",
"     <li>",
"      Betaloc Zoc (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Betaloc Zok (CL, CO, EC, EE, HK, HU, PE, PK, PL, TH, TW);",
"     </li>",
"     <li>",
"      Betawin (MY);",
"     </li>",
"     <li>",
"      Betazok (PH);",
"     </li>",
"     <li>",
"      Bloxan (HR);",
"     </li>",
"     <li>",
"      Cardeloc (TH);",
"     </li>",
"     <li>",
"      Cardiosel (PH);",
"     </li>",
"     <li>",
"      Cardiostat (PH);",
"     </li>",
"     <li>",
"      Cardiotab (PH);",
"     </li>",
"     <li>",
"      Denex (MY, SG);",
"     </li>",
"     <li>",
"      Fapresor (ID);",
"     </li>",
"     <li>",
"      Huma-Metoprol (HU);",
"     </li>",
"     <li>",
"      Hypetor (PH);",
"     </li>",
"     <li>",
"      Jutabloc (DE);",
"     </li>",
"     <li>",
"      Lofarbil (GR);",
"     </li>",
"     <li>",
"      Lopresor (AE, AR, AT, AU, BB, BE, BF, BH, BJ, BM, BS, BZ, CI, CN, CY, CZ, EG, ES, ET, GB, GH, GM, GN, GR, GY, IE, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, NE, NG, NL, NZ, OM, PT, PY, QA, SA, SC, SD, SL, SN, SR, SY, TN, TR, TT, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Lopresor Divitab (IL);",
"     </li>",
"     <li>",
"      Lopresor OROS (LU);",
"     </li>",
"     <li>",
"      Lopresor Retard (AT, CH, GR, IT, PT);",
"     </li>",
"     <li>",
"      Lopresor SR (GB);",
"     </li>",
"     <li>",
"      Lopressor (BR, FR);",
"     </li>",
"     <li>",
"      Loprolol (ID);",
"     </li>",
"     <li>",
"      Meto-Hennig (DE);",
"     </li>",
"     <li>",
"      Metohexal (AU, HU, LU);",
"     </li>",
"     <li>",
"      Metolol-CP (HK);",
"     </li>",
"     <li>",
"      Metop (IE);",
"     </li>",
"     <li>",
"      Metoprim (PH);",
"     </li>",
"     <li>",
"      Metoprogamma (DE);",
"     </li>",
"     <li>",
"      Metoprolol Stada (HU);",
"     </li>",
"     <li>",
"      Metoprolol-B (HU);",
"     </li>",
"     <li>",
"      Metoprolol-rpm (LU);",
"     </li>",
"     <li>",
"      Metostad (PH);",
"     </li>",
"     <li>",
"      Metrol (AU);",
"     </li>",
"     <li>",
"      Mezelol (MX);",
"     </li>",
"     <li>",
"      Minax (AU, HK, TW);",
"     </li>",
"     <li>",
"      Mycol CR (NZ);",
"     </li>",
"     <li>",
"      Neobloc (IL);",
"     </li>",
"     <li>",
"      Nipresol (MX);",
"     </li>",
"     <li>",
"      Promiced (MX);",
"     </li>",
"     <li>",
"      Ritmetol (HU);",
"     </li>",
"     <li>",
"      Sefloc (TH);",
"     </li>",
"     <li>",
"      Selo-zok (DK, NO);",
"     </li>",
"     <li>",
"      Selokeen (NL);",
"     </li>",
"     <li>",
"      Seloken (BE, DK, FI, FR, ID, IT, JP, NO, SE);",
"     </li>",
"     <li>",
"      Seloken Retard (AT, IT);",
"     </li>",
"     <li>",
"      Seloken Zoc (FI, SE);",
"     </li>",
"     <li>",
"      Seloken-Zok (MX);",
"     </li>",
"     <li>",
"      Selopral (FI);",
"     </li>",
"     <li>",
"      Selozok (BE, DK, LU);",
"     </li>",
"     <li>",
"      Selozok LP (FR);",
"     </li>",
"     <li>",
"      Slow-Lopresor (LU, NZ);",
"     </li>",
"     <li>",
"      Tadilor (DO);",
"     </li>",
"     <li>",
"      Toprol XL (AU);",
"     </li>",
"     <li>",
"      Vasocardin (BG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F195755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective inhibitor of beta",
"     <sub>",
"      1",
"     </sub>",
"     -adrenergic receptors; competitively blocks beta",
"     <sub>",
"      1",
"     </sub>",
"     -receptors, with little or no effect on beta",
"     <sub>",
"      2",
"     </sub>",
"     -receptors at doses &lt;100 mg; does not exhibit any membrane stabilizing or intrinsic sympathomimetic activity",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F195774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect: Oral: 1-2 hours (Reg&aring;rdh, 1980); I.V.: 20 minutes (when infused over 10 minutes)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Oral: Immediate release: Variable (dose-related; 50% reduction in maximum heart rate after single doses of 20, 50, and 100 mg occurred at 3.3, 5, and 6.4 hours, respectively), Extended release: ~24 hours; I.V.: 5-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 3.2-5.6 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~10% to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via CYP2D6; significant first-pass effect (~50%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: Immediate release: ~50% (Extended release: 77% relative to immediate release)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 3-4 hours (7-9 hours in poor CYP2D6 metabolizers)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;10% as unchanged drug; increased to 30-40% in poor CYP2D6 metabolizers)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/11533352 /pubmed\" id=\"11533352 \" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, \"2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(18):e426-579.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/21444888/pubmed\" id=\"21444888\" target=\"_blank\">",
"        21444888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe DT, Armstrong PW, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(9):e82-292.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/15339869/pubmed\" id=\"15339869\" target=\"_blank\">",
"        15339869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronow WS, Fleg JL, Pepine CJ, et al, &ldquo;ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(21):2434-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/21518977/pubmed\" id=\"21518977\" target=\"_blank\">",
"        21518977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bahn RS (Chair), Burch HB, Cooper DS, et al, &ldquo;Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists,&rdquo;",
"      <i>",
"       Thyroid",
"      </i>",
"      , 2011, 21(6):593-646.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/ 21510801/pubmed\" id=\" 21510801\" target=\"_blank\">",
"        21510801",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Biffi M, Boriani G, Sabbatani P, et al, &ldquo;Malignant Vasovagal Syncope: A Randomised Trial of Metoprolol and Clonidine,&rdquo;",
"      <i>",
"       Heart",
"      </i>",
"      , 1997, 77(3):268-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/9093048/pubmed\" id=\"9093048\" target=\"_blank\">",
"        9093048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blomstr&ouml;m-Lundqvist C, Scheinman MM, Aliot EM, et al, &ldquo;ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias--Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 108(15):1871-909.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/14557344/pubmed\" id=\"14557344\" target=\"_blank\">",
"        14557344",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brauchli YB, Jick SS, Curtin F, et al, &ldquo;Association Between Beta-Blockers, Other Antihypertensive Drugs and Psoriasis: Population-Based Case-Control Study,&rdquo;",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 2008, 158(6):1299-307.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/18410416/pubmed\" id=\"18410416\" target=\"_blank\">",
"        18410416",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chen ZM, Pan HC, Chen YP, et al, &ldquo;Early Intravenous Then Oral Metoprolol in 45,852 Patients With Acute Myocardial Infarction: Randomized Placebo Controlled Trial. COMMIT Collaborative Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2005, 366(9497):1622-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/16271643/pubmed\" id=\"16271643\" target=\"_blank\">",
"        16271643",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Delacr&eacute;taz E, &ldquo;Clinical Practice: Supraventricular Tachycardia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(10):1039-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/16525141/pubmed\" id=\"16525141\" target=\"_blank\">",
"        16525141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Effect of Metoprolol CR/XL in Chronic Heart Failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF),&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1999, 353(9169):2001-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/10376614/pubmed\" id=\"10376614\" target=\"_blank\">",
"        10376614",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122 (18 Suppl 3):640-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/20956217/pubmed\" id=\"20956217\" target=\"_blank\">",
"        20956217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fleisher LA, Beckman JA, Brown KA, et al, &ldquo;2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(22):e13-118.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/19926002/pubmed\" id=\"19926002\" target=\"_blank\">",
"        19926002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuster V, Ryden LE, Cannom DS, et al, &ldquo;ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(4):854-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/16904574 /pubmed\" id=\"16904574 \" target=\"_blank\">",
"        16904574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Geffner DL and Hershman JM, &ldquo;beta-Adrenergic Blockade for the Treatment of Hyperthyroidism,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1992, 93(1):61-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/1352658/pubmed\" id=\"1352658\" target=\"_blank\">",
"        1352658",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hazard PB and Burnett CR, &ldquo;Treatment of Multifocal Atrial Tachycardia With Metoprolol,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1987, 15(1):20-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/3792010/pubmed\" id=\"3792010\" target=\"_blank\">",
"        3792010",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hirsch AT, Haskal ZJ, Hertzer NR, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): Executive Summary. A Collaborative Report of the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2006, 113(11):1474-1547.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/16549646/pubmed\" id=\"16549646\" target=\"_blank\">",
"        16549646",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Juul AB, Wetterslev J, Gluud C, et al, &ldquo;Effect of Perioperative Beta Blockade in Patients With Diabetes Undergoing Major Non-Cardiac Surgery: Randomized Placebo Controlled, Blinded Multicentre Trial. DIPOM Trial Group,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 2006, 332(7556):1482.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/16793810/pubmed\" id=\"16793810\" target=\"_blank\">",
"        16793810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kukin ML, Kalman J, Charney RH, et al, &ldquo;Prospective, Randomized Comparison of Effect of Long-Term Treatment With Metoprolol or Carvedilol on Symptoms, Exercise, Ejection Fraction, and Oxidative Stress in Heart Failure,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 99(2):2645-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/10338457/pubmed\" id=\"10338457\" target=\"_blank\">",
"        10338457",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lang DM, &ldquo;Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1995, 12(5):299-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/7669259/pubmed\" id=\"7669259\" target=\"_blank\">",
"        7669259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenauer PK, Pekow P, Wang K, et al, &ldquo;Perioperative Beta-Blocker Therapy and Mortality After Major Noncardiac Surgery,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 353(4):349-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/16049209/pubmed\" id=\"16049209\" target=\"_blank\">",
"        16049209",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76. Available at file://www.pediatrics.org/cgi/content/full/114/2/S2/555",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neumar RW, Otto CW, Link MS, et al, &ldquo;Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):729-67.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nishimura RA and Holmes DR, &ldquo;Clinical Practice. Hypertrophic Obstructive Cardiomyopathy,&rdquo;",
"      <i>",
"       N Engl M Med",
"      </i>",
"      , 2004, 350(13):1320-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/15044643/pubmed\" id=\"15044643\" target=\"_blank\">",
"        15044643",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al, \"2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 127(4):e362-425.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/3247304/pubmed\" id=\"3247304\" target=\"_blank\">",
"        3247304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olsson G, Wikstrand J, Warnold I, et al, &ldquo;Metoprolol-Induced Reduction in Postinfarction Mortality: Pooled Results From Five Double-Blind Randomized Trials,&rdquo;",
"      <i>",
"       Eur Heart J",
"      </i>",
"      , 1992, 13(1):28-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/1533587/pubmed\" id=\"1533587\" target=\"_blank\">",
"        1533587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      POISE Study Group, Devereaux PJ, Yang H, et al, &ldquo;Effects of Extended-Release Metoprolol Succinate in Patients Undergoing Non-Cardiac Surgery (POISE Trial): A Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2008, 371(9627):1839-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/18479744/pubmed\" id=\"18479744\" target=\"_blank\">",
"        18479744",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Poole-Wilson PA, Swedberg K, Cleland JG, et al, &ldquo;Comparison of Carvedilol and Metoprolol on Clinical Outcomes in Patients With Chronic Heart Failure in the Carvedilol or Metoprolol European Trial (COMET): Randomized Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9377):7-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/12853193/pubmed\" id=\"12853193\" target=\"_blank\">",
"        12853193",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rabins PV, Blacker D, Rovner BW, et al, &ldquo;American Psychiatric Association Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(12 Suppl):5-56. Available at file://psychiatryonline.org/guidelines.aspx",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/18340692/pubmed\" id=\"18340692\" target=\"_blank\">",
"        18340692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Radack K and Deck C, &ldquo;Beta-Adrenergic Blocker Therapy Does Not Worsen Intermittent Claudication in Subjects With Peripheral Arterial Disease. A Meta-Analysis of Randomized Controlled Trials,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1991, 151(9):1769-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/1679624/pubmed\" id=\"1679624\" target=\"_blank\">",
"        1679624",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Redelmeier D, Scales D, and Kopp A, &ldquo;Beta Blockers for Elective Surgery in Elderly Patients: Population Based, Retrospective Cohort Study,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 2005, 331(7522):932.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/16210252/pubmed\" id=\"16210252\" target=\"_blank\">",
"        16210252",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reg&aring;rdh CG and Johnsson G, \"Clinical Pharmacokinetics of Metoprolol,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1980, 5(6):557-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/7002420/pubmed\" id=\"7002420\" target=\"_blank\">",
"        7002420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sch&ouml;n MP and Boehncke WH, &ldquo;Psoriasis,&rdquo;",
"      <i>",
"       N Eng J Med",
"      </i>",
"      , 2005, 352(18):1899-1912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/15872205/pubmed\" id=\"15872205\" target=\"_blank\">",
"        15872205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silberstein SD, Holland S, Freitag F, et al, &ldquo;Evidence-Based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults: Report of the Quality Standard Subcommittee of the American Academy of Neurology and the American Headache Society,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2012, 78(17):1337-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/22529202/pubmed\" id=\"22529202\" target=\"_blank\">",
"        22529202",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Skanes AC, Healey JS, Cairns JA, et al, &ldquo;Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2012, 28(2):125-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/22433576/pubmed\" id=\"22433576\" target=\"_blank\">",
"        22433576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      UK Prospective Diabetes Study Group, &ldquo;Efficacy of Atenolol and Captopril in Reducing Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 39,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1998, 317(7160):713-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/9732338/pubmed\" id=\"9732338\" target=\"_blank\">",
"        9732338",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vozeh S, Schmidlin O, and Taeschner W, &ldquo;Pharmacokinetic Drug Data,&rdquo;",
"      <i>",
"       Clin Pharmacokinetics",
"      </i>",
"      , 1988, 15(4):254-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/3191648/pubmed\" id=\"3191648\" target=\"_blank\">",
"        3191648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Waagstein F, Bristow MR, Swedberg K, et al, &ldquo;Beneficial Effects of Metoprolol in Idiopathic Dilated Cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1993, 342(8885):1441-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/7902479/pubmed\" id=\"7902479\" target=\"_blank\">",
"        7902479",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wann SL, Curtis AB, January CT, et al, &ldquo;2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123 (1):104-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/21173346/pubmed\" id=\"21173346\" target=\"_blank\">",
"        21173346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yang H, Raymer K, Butler R, et al, &ldquo;The Effects of Perioperative Beta-Blockade: Results of the Metoprolol After Vascular Surgery (MaVS) Study, a Randomized Controlled Trial,&rdquo;",
"      <i>",
"       Am Hear J",
"      </i>",
"      , 2006, 152(5):983-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/31/39417/abstract-text/17070177/pubmed\" id=\"17070177\" target=\"_blank\">",
"        17070177",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9645 Version 54.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-188.40.116.55-F65976BBC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_31_39417=[""].join("\n");
var outline_f38_31_39417=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709042\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195796\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195797\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195848\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195801\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195823\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195802\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5660888\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195804\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195767\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195752\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195771\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195855\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195770\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195844\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195857\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195846\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195775\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195756\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195842\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195761\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195792\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195763\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195778\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195808\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195779\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195780\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195777\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195765\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195781\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195755\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195774\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9645\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9645|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/28/25030?source=related_link\">",
"      Metoprolol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/11/15544?source=related_link\">",
"      Metoprolol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_31_39418="Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus";
var content_f38_31_39418=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"37\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/31/39418/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/31/39418/contributors\">",
"     Noah C Choi, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/31/39418/contributors\">",
"     Michael K Gibson, MD, PhD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/31/39418/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/31/39418/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/31/39418/contributors\">",
"     Christopher G Willett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/31/39418/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/31/39418/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/31/39418/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer of the esophagus is a highly lethal malignancy. There are approximately 17,990 people diagnosed with esophageal cancer each year in the United States and 15,210 deaths from the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/1\">",
"     1",
"    </a>",
"    ]. Data on global incidence and mortality are available from the World Health Organization",
"    <a class=\"external\" href=\"file://globocan.iarc.fr/\">",
"     GLOBOCAN database",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    According to data from the US Surveillance, Epidemiology and End Results (SEER) Program, the five-year survival for all patients with esophageal cancer improved only modestly over the last 30 years, from 5 percent in the years 1975 to 1977, to 19 percent during the period 2001 to 2007 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/2\">",
"     2",
"    </a>",
"    ]. These sobering figures are indicative of the advanced stage of disease (local-regional or metastatic) at diagnosis in most patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of local-regional esophageal cancer has undergone a major evolution over the past 15 years. The low cure rates after locoregional therapy alone prompted the inclusion of systemic chemotherapy in multimodality treatment regimens, to control distant micrometastatic disease and enhance local radiation effects. The seminal RTOG 85-01 trial demonstrated a survival benefit for the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy to radiation therapy (RT) in non-surgically treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]; whether induction chemoradiotherapy adds benefit to surgery for potentially resectable disease remains a controversial area. Fewer than one-third of all patients are cured by multimodality therapy, and distant failure accounts for three-fourths of all recurrences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Classification and management of esophagogastric junction (EGJ) tumors has also evolved over time. In the latest edition of the TNM staging manual, tumors arising at the EGJ or in the cardia of the stomach within 5 cm of the EGJ that extend into the EGJ or esophagus are staged as esophageal rather than stomach cancers, while those that arise within 5 cm of the EGJ but without extension into the esophagus are still staged as gastric cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7898?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis and staging of esophageal cancer\", section on 'TNM staging criteria'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11850?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features, diagnosis, and staging of gastric cancer\", section on 'TNM staging criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most clinicians now treat EGJ and proximal gastric (ie, cardia, (",
"    <a class=\"graphic graphic_figure graphicRef56689 \" href=\"mobipreview.htm?40/59/41907\">",
"     figure 1",
"    </a>",
"    )) cancers as esophageal cancers, using preoperative chemoradiotherapy. However, these tumors have been included in many of the trials examining the benefit of adjuvant and neoadjuvant chemotherapy for gastric cancer, and institutional practice varies. Management of EGJ and gastric cardia tumors is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/51/39738?source=see_link\">",
"     \"Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will focus on the efficacy of RT and chemotherapy and multimodality management of localized and locoregional cancer involving the thoracic esophagus. Management of cervical esophageal tumors is also considered briefly.",
"   </p>",
"   <p>",
"    Multimodality approaches to cancer of the esophagogastric junction (EGJ), neoadjuvant and adjuvant approaches for true gastric tumors, principles of surgical treatment for localized esophageal and EGJ cancer, nutritional support during multimodality therapy, endoscopic methods for palliation of dysphagia during neoadjuvant treatment, issues specific to superficial and locally advanced unresectable disease, and treatment of metastatic disease are discussed elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/51/39738?source=see_link\">",
"       \"Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11882?source=see_link\">",
"       \"Adjuvant and neoadjuvant treatment of gastric cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/30/34282?source=see_link\">",
"       \"Surgical oncologic principles for management of resectable esophageal cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29770?source=see_link\">",
"       \"The role of parenteral and enteral/oral nutritional support in patients with cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/41/6809?source=see_link&amp;anchor=H3#H3\">",
"       \"Expandable stents in the treatment of esophageal obstruction\", section on 'Self-expandable plastic stents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42006?source=see_link\">",
"       \"Endoscopic palliation of esophageal cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/60/20426?source=see_link\">",
"       \"Management of superficial esophageal cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30106?source=see_link\">",
"       \"Management of locally advanced unresectable esophageal cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/10/44202?source=see_link\">",
"       \"Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SQUAMOUS CELL VERSUS ADENOCARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major histologies of esophageal cancer: squamous cell cancer (SCC) and adenocarcinoma. Although most clinical studies have not differentiated between the two histologies, an increasing amount of evidence supports the view that they differ in terms of pathogenesis, epidemiology, tumor biology, and prognosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of SCC is declining in the US while that of adenocarcinoma has increased markedly over the last 20 years, suggesting underlying etiologic differences. SCC is almost always the result of tobacco",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      alcohol abuse while adenocarcinomas are associated with gastroesophageal reflux disease (GERD) and high body mass [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/8-10\">",
"       8-10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32250?source=see_link\">",
"       \"Epidemiology, pathobiology, and clinical manifestations of esophageal cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The precursor lesion of SCC is epithelial dysplasia, which progresses in sequence to carcinoma in situ, and finally to invasive carcinoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/11\">",
"       11",
"      </a>",
"      ]. In contrast, adenocarcinomas usually arise as a consequence of persistent GERD, in which the mucosa of the distal esophagus undergoes intestinal metaplasia. Carcinogenesis begins with genetic alterations which endow the metaplastic cells with a growth advantage, permitting them to hyperproliferate. As the cells progressively acquire DNA damage, they become morphologically dysplastic, and eventually, frankly malignant. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/12/8391?source=see_link&amp;anchor=H6#H6\">",
"       \"Pathogenesis of Barrett's esophagus and its malignant transformation\", section on 'Adenocarcinoma arising from Barrett's'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although SCCs tend to arise 10 years earlier, on average, than adenocarcinomas, perioperative mortality is higher for SCC than for a Barrett's adenocarcinoma, likely related to associated comorbidity and tumor location [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/10,12\">",
"       10,12",
"      </a>",
"      ]. The sequelae of GERD involve mostly the distal",
"      <span class=\"nowrap\">",
"       esophagus/EGJ,",
"      </span>",
"      and 94 percent of cancers associated with Barrett's esophagus are located below the tracheal bifurcation. In contrast, 65 percent of SCCs are located above this location [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/13\">",
"       13",
"      </a>",
"      ]. Tumors located in the upper third of the esophagus have significantly higher rates of postoperative death. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/30/34282?source=see_link\">",
"       \"Surgical oncologic principles for management of resectable esophageal cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32250?source=see_link\">",
"       \"Epidemiology, pathobiology, and clinical manifestations of esophageal cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/12/8391?source=see_link\">",
"       \"Pathogenesis of Barrett's esophagus and its malignant transformation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Histology also influences the pattern of first recurrence after resection. Upper or mid-thoracic SCCs (",
"      <a class=\"graphic graphic_figure graphicRef76958 \" href=\"mobipreview.htm?4/36/4678\">",
"       figure 2",
"      </a>",
"      ) tend to recur locoregionally first, while distal esophageal adenocarcinomas more commonly recur with distant dissemination.",
"      <br/>",
"      <br/>",
"      Despite these data, many (but not all [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/14\">",
"       14",
"      </a>",
"      ]) contemporary series suggest that the prognosis of adenocarcinoma is better than that of SCC, particularly in early stage disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/8,9,14-18\">",
"       8,9,14-18",
"      </a>",
"      ]. One reason may be the lower prevalence of lymphatic spread for Barrett's-associated cancer than for SCCs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/8,14\">",
"       8,14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It has been proposed that the difference in tumor location also has implications for the choice of therapy. Some suggest that induction chemotherapy alone may suffice for adenocarcinomas, while results are superior with chemoradiotherapy for SCCs because of the greater need for tumor downsizing to achieve a complete radical resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/8\">",
"     8",
"    </a>",
"    ]. However, there are few data to support this viewpoint and little agreement as to whether histologic type should be used as a factor in selecting the treatment strategy. A major area where data are lacking is nonsurgical management for adenocarcinomas. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Necessity for surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H964957130\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;In summary, there seems little doubt that esophageal SCC and adenocarcinoma represent two different diseases with characteristic pathogenesis, epidemiology, tumor biology, and outcomes. In acknowledgement of these differences, the most recent 2010 TNM staging system provides separate stage groupings (but similar definitions for T, N, M and grade [G] categories) for SCCs and adenocarcinomas of the esophagus and EGJ (",
"    <a class=\"graphic graphic_table graphicRef62895 \" href=\"mobipreview.htm?13/38/13934\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52078 \" href=\"mobipreview.htm?4/24/4494\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, tumor location (for SCCs only) was incorporated into stage grouping. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7898?source=see_link\">",
"     \"Diagnosis and staging of esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, it remains unclear as to whether and how histology should dictate the therapeutic approach. Future studies in esophageal cancer should analyze and report separately the results of therapeutic strategies according to histology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H486068\">",
"    <span class=\"h1\">",
"     THORACIC ESOPHAGUS TUMORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Surgery alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although only 30 to 40 percent of patients have potentially resectable disease at presentation, surgery has been the standard treatment for early stage esophageal cancer. Its utility as monotherapy has been challenged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Data from contemporary surgical series report five-year survival rates of 15 to 20 percent for surgery alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/6,21-24\">",
"     6,21-24",
"    </a>",
"    ]. In an analysis of 4627 patients with esophageal cancer who were treated with surgery alone without adjuvant or neoadjuvant therapy, five-year survival rates were &lt;50 percent for all disease stages except stage I (T1N0 according to the 6",
"    <sup>",
"     th",
"    </sup>",
"    edition of the AJCC TNM staging system), and they were 15 percent for any patient with node-positive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This poor long-term outcome has prompted an evaluation of neoadjuvant (preoperative), adjuvant (postoperative), and nonoperative strategies aimed at improving survival in patients with apparently localized disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/30/34282?source=see_link&amp;anchor=H7377436#H7377436\">",
"     \"Surgical oncologic principles for management of resectable esophageal cancer\", section on 'Thoracic cancer resection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     RT alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before the era of modern chemotherapy and combined chemoradiotherapy, RT alone (60 to 66 Gy over a period of 6 to 6.6 weeks) was associated with five-year survival rates of 5 to 20 percent, depending upon tumor extent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. In a review of 49 early series involving more than 8400 patients treated with RT alone, survival rates at one, two, and five years were 18, 8, and 6 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Better results are reported in later studies from single institutions in well-defined patient populations using modern RT protocols. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three- and five-year survival rates of 27 and 21 percent, respectively, were observed in a series of 101 selected patients (11 adenocarcinomas) with clinically localized disease treated with RT alone (45 to 52.5 Gy in 15 or 16 fractions over three weeks) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a cohort of 17 patients with clinical stage I esophageal SCC (after endoscopic ultrasound [EUS] and CT) treated with RT alone (median 60.6 Gy), the five-year survival rate was 59 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Modern techniques (eg, three-dimensional conformal RT [3D-CRT], intensity modulated RT [IMRT]) are associated with more favorable toxicity profiles than those associated with the lower energy units used in earlier years. The success of advanced radiation technology can be illustrated by a preliminary report of a Chinese trial in which surgery was compared to RT alone in 269 patients with esophageal SCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/31\">",
"     31",
"    </a>",
"    ]. RT was planned using 3D-CRT technique, and 69 Gy were delivered in 41 fractions over 45 days (45 Gy in 25 fractions over five weeks followed by 24 Gy in twice daily 1.5 Gy fractions for eight days using IMRT). Three- and five-year overall survival rates in the RT alone group (61 and 37 percent, respectively) were not significantly different from those in the surgery group (56 and 35 percent, respectively). These results cannot be extrapolated to patients with adenocarcinoma.",
"   </p>",
"   <p>",
"    Although these data are encouraging, the role of RT alone has been supplanted by combined chemoradiotherapy in the majority of patients, despite a higher rate of treatment-related toxicity. Combined IMRT and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy is under study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concomitant chemotherapy and RT has been studied as definitive nonoperative treatment and in the preoperative (neoadjuvant) setting. The more recent strategy of using chemotherapy alone as induction therapy prior to surgery is discussed below (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Neoadjuvant chemotherapy'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Definitive chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concurrent chemoradiotherapy permits maximal tumor control because the combined local antitumor effect is more than additive (a therapeutic advantage termed radiation sensitization), and chemotherapy provides the opportunity for control of micrometastatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/32-34\">",
"     32-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In randomized trials, the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy to RT significantly improves survival over RT alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/4,5,35\">",
"     4,5,35",
"    </a>",
"    ]. However, the available data are almost exclusively in SCC, and none of the trials have performed adequate pretreatment staging to reliably correlate outcome with locoregional tumor extent (ie, locally advanced unresectable versus potentially operable disease). The following sections will summarize the data for patients with disease confined to the primary and regional nodes based upon radiographic imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h4\">",
"     RTOG 85-01",
"    </span>",
"    &nbsp;&mdash;&nbsp;A landmark RTOG trial compared RT alone (64 Gy in 32 fractions over 6.5 weeks) versus concurrent chemoradiotherapy (two cycles of infusional FU [1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day, days 1 to 4, weeks 1 and 5] plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    day 1 of weeks 1 and 5] and RT [50 Gy in 25 fractions over five weeks]) in patients with locoregional thoracic esophageal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients were required to have no evidence of spread beyond mediastinal and supraclavicular lymph nodes; 90 percent had SCC. The chemoradiotherapy group received two additional chemotherapy courses, three weeks apart, after RT. Surgery was not part of the treatment schema.",
"   </p>",
"   <p>",
"    The trial was closed prematurely with 121 patients, when an interim analysis showed a significant survival advantage for chemoradiotherapy (five-year survival 27 versus 0 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/5\">",
"     5",
"    </a>",
"    ]. Analysis of failure patterns showed a significant reduction in both locoregional and distant failure for chemoradiotherapy. However, despite this benefit, 46 percent of patients in the chemoradiotherapy group had locally recurrent or persistent disease in the esophagus at 12 months. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Necessity for surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As a result of this trial, definitive chemoradiotherapy became the standard of care for patients with inoperable disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30106?source=see_link\">",
"     \"Management of locally advanced unresectable esophageal cancer\"",
"    </a>",
"    .) The issue of the unacceptably high locoregional failure rate was addressed in a follow-up trial, INT 0123.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h4\">",
"     Intergroup 0123",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the US Intergroup Study 0123 (INT 0123), 236 patients with nonmetastatic esophageal SCC or adenocarcinoma received concurrent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and FU (as in RTOG 85-01), but they were randomly assigned to one of two different RT doses: 50.4 Gy (28 fractions of 1.8 Gy each, five fractions per week) or 64.8 Gy (36 fractions of 1.8 Gy each, five fractions per week) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/36\">",
"     36",
"    </a>",
"    ]. Higher RT doses were not associated with a higher median (13 versus 18 months) or two-year survival (31 versus 40 percent), or the incidence of locoregional persistent or recurrent disease (56 versus 52 percent for the high dose and control groups, respectively). High-dose RT was significantly more toxic.",
"   </p>",
"   <p>",
"    The reason for the failure to demonstrate better survival or locoregional control with higher RT doses is unclear. At present, 50 Gy of RT plus concurrent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and FU remains a standard approach.",
"   </p>",
"   <p>",
"    More recent studies are investigating the role of newer chemotherapy drugs combined with RT. Many of these trials are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30106?source=see_link&amp;anchor=H25#H25\">",
"     \"Management of locally advanced unresectable esophageal cancer\", section on 'Chemotherapy intensification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Elderly patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few data are available on the safety and efficacy of chemoradiotherapy in the elderly. However, at least one report suggests that patients over age 70 tolerate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemoradiotherapy without a major increase in adverse events and with outcomes that seem comparable to those achieved in younger individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/37\">",
"     37",
"    </a>",
"    ]. However, patients with significant comorbidity (ie, Charlson score &ge;1, (",
"    <a class=\"graphic graphic_table graphicRef72047 \" href=\"mobipreview.htm?25/40/26252\">",
"     table 3",
"    </a>",
"    )) experienced more severe toxicity and chemotherapy",
"    <span class=\"nowrap\">",
"     delays/dose",
"    </span>",
"    reductions than those without comorbidity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=see_link\">",
"     \"Comprehensive geriatric assessment for patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether results with definitive chemoradiotherapy are as good as can be obtained with esophagectomy in elderly patients with early stage esophageal cancer is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Preoperative chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The poor long-term survival associated with surgery alone and the radiosensitizing effect of concurrent chemotherapy provided the impetus to evaluate preoperative chemoradiotherapy. At least seven trials have directly compared surgery with or without preoperative chemoradiotherapy for patients with potentially resectable esophageal carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/21,39-44\">",
"     21,39-44",
"    </a>",
"    ]. Two demonstrate a significant survival benefit from combined modality therapy, both using a concurrent rather than sequential approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Concurrent chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the five completed randomized trials compared preoperative concurrent chemoradiotherapy versus surgery alone, only two show a statistically significant survival benefit for chemoradiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/43,45\">",
"     43,45",
"    </a>",
"    ], three others do not, two of which were underpowered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/39,44,46\">",
"     39,44,46",
"    </a>",
"    ]. Of these, the two most important are the Dutch CROSS trial and CALGB 9781.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4965589\">",
"    <span class=\"h5\">",
"     CROSS trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dutch investigators randomly assigned 363 patients with potentially resectable esophageal or EGJ cancer (86 SCC, 273 adenocarcinoma, four other; majority distal esophageal, 11 percent EGJ) to preoperative chemoradiotherapy using weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    (area under the curve of concentration X time [AUC] of 2) plus concurrent RT (41.4 Gy over five weeks) or surgery alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/47\">",
"     47",
"    </a>",
"    ]. Preoperative chemoradiotherapy was well tolerated, with grade 3 or worse hematologic toxicity in 7 percent, and grade 3 or higher non-hematologic toxicity in &lt;13 percent; there were also no differences in postoperative morbidity or mortality between the two groups. The complete (R0) resection rate was higher with chemoradiotherapy (92 versus 69 percent), and 29 percent of those treated with chemoradiotherapy had a pCR. At a median follow-up of 32 months, median overall survival was significantly better with preoperative chemoradiotherapy (hazard ratio for death 0.657, 95% CI 0.495-0.871, three-year survival rate 58 versus 44 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4965660\">",
"    <span class=\"h5\">",
"     CALGB 9781",
"    </span>",
"    &nbsp;&mdash;&nbsp;CALGB 9781 was originally designed as a randomized Intergroup trial of trimodality therapy versus surgery in 500 patients with stages I-III esophageal or EGJ cancer, staged with esophagogastroduodenoscopy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    esophagram, and CT. Staging EUS and",
"    <span class=\"nowrap\">",
"     thoracoscopy/laparoscopy",
"    </span>",
"    were encouraged. Due to poor accrual, the study was closed prematurely with only 56 patients enrolled (42 adenocarcinomas, 14 SCC).",
"    <br/>",
"    <br/>",
"    A pCR was achieved in 10 of 25 assessable patients in the trimodality arm (40 percent), and neither perioperative morbidity nor mortality were increased compared to surgery alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/44\">",
"     44",
"    </a>",
"    ]. Five-year survival was 39 versus 16 percent in favor of trimodality therapy, although the difference was not statistically significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4965704\">",
"    <span class=\"h5\">",
"     Early stage disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trimodality treatment should not be used for stage I esophageal cancer, as it is best assessed by endoscopic ultrasound. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7898?source=see_link&amp;anchor=H9#H9\">",
"     \"Diagnosis and staging of esophageal cancer\", section on 'Locoregional staging with EUS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefit of preoperative chemoradiotherapy in smaller resectable tumors was addressed in the French FFCD 9901 trial, which randomly assigned 195 patients with stage I or II esophageal or EGJ cancer",
"    <span class=\"nowrap\">",
"     (T1N0/N+,",
"    </span>",
"    T2",
"    <span class=\"nowrap\">",
"     N0/N+,",
"    </span>",
"    or T3N0, (",
"    <a class=\"graphic graphic_table graphicRef62895 \" href=\"mobipreview.htm?13/38/13934\">",
"     table 1",
"    </a>",
"    )) to preoperative chemoradiotherapy (two courses of infusional",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    800",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily days 1 to 4 and 29 to 32 plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1 or 2 of each course and concurrent RT [45 Gy]) versus surgery alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/46\">",
"     46",
"    </a>",
"    ]. In a preliminary report of an interim analysis, at a median followup of 69 months, neoadjuvant chemoradiotherapy did not improve median overall survival (32 versus 44 months with surgery alone), and it was associated with significantly more serious adverse events (65 versus 35 percent) and a significantly higher rate of perioperative mortality (7.3 versus 1.1 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h4\">",
"     Sequential chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the data on concurrent chemoradiotherapy, at least three trials comparing sequentially administered chemotherapy and RT followed by surgery to surgery alone have failed to show any survival advantage to combined modality therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/21,40,41\">",
"     21,40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h4\">",
"     Meta-analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several meta-analyses have addressed the benefit of trimodality therapy over surgery alone for esophageal cancer. The most recent and largest of these included 12 randomized comparisons of neoadjuvant chemoradiotherapy (either concurrent or sequential) versus surgery alone for esophageal or EGJ cancer, including the FFCD 9901, CALGB 9781, and CROSS trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/48\">",
"     48",
"    </a>",
"    ]. The hazard ratio (HR) for all-cause mortality for neoadjuvant chemoradiotherapy was 0.78 (95% CI 0.70-0.88), and this translated into an absolute survival benefit of 8.7 percent at two years and a number needed to treat to prevent one death of 11. The benefit was similar across histologic subtypes (for SCC, the HR was 0.80, 95% CI 0.68-0.93; for adenocarcinomas, the HR was 0.75, 95% CI 0.59-0.95). The potential benefit of neoadjuvant therapy was not offset by a higher postoperative mortality (in-hospital or 30-day postoperative death).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H336671321\">",
"    <span class=\"h4\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;With several trials and at meta-analyses demonstrating better survival with preoperative concurrent chemoradiation, combined modality therapy for potentially resectable stage II or III localized cancer of the thoracic esophagus is generally preferred over local therapy alone. However, for patients who do undergo preoperative concurrent chemoradiotherapy, the optimal regimen is not established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H336671859\">",
"    <span class=\"h3\">",
"     Intensification of preoperative therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A consistent finding in many studies is that response to preoperative therapy, particularly the absence of residual disease in the surgical specimen, is an indicator of better disease-free and overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/39,49-59\">",
"     39,49-59",
"    </a>",
"    ]. In a comprehensive literature review of 22 studies in which patients with esophageal or GEJ cancer underwent esophagectomy after neoadjuvant chemoradiotherapy, patients with a pCR were two- to threefold more likely to survive as were those with residual disease in the esophagectomy specimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/59\">",
"     59",
"    </a>",
"    ]. These benefits translate into a 33 to 36 percent mean absolute survival benefit when a pCR is achieved than when it is not.",
"   </p>",
"   <p>",
"    These results provide the rationale for intensification of preoperative treatment through adding several cycles of induction chemotherapy prior to preoperative chemoradiation, or increasing the number of cytotoxic agents administered concurrent with RT.",
"   </p>",
"   <p>",
"    Several groups have reported their experience with sequential induction chemotherapy followed by chemoradiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/60-65\">",
"     60-65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While no randomized trials have compared this sequential induction chemotherapy followed by chemoradiotherapy to standard chemoradiotherapy, there are two trials comparing this approach to surgery alone or induction chemotherapy followed by surgery:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A Swedish trial compared one course of preoperative induction chemotherapy followed by concurrent chemoradiotherapy versus surgery alone in 91 patients with resectable esophageal cancer (50 percent SCC) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/64\">",
"       64",
"      </a>",
"      ]. Patients randomized to preoperative treatment received three cycles of chemotherapy (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1 plus infusional FU 750",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily, days 1 to 5), with the first course given prior to and the next two concurrent with RT (64 Gy). In a preliminary report, at a median follow-up of 52 months, median survival was 13 months for the chemoradiotherapy group and 16 months for the surgery alone group, and four- year survival was not significantly better in the chemoradiotherapy group (29 versus 23 percent). The RT dose was much higher than that established in RTOG 85-01 (see",
"      <a class=\"local\" href=\"#H8\">",
"       'RTOG 85-01'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The only trial to directly compare induction chemotherapy followed by concurrent chemoradiotherapy versus induction chemotherapy alone was the German POET trial, in which 126 patients with EGJ adenocarcinoma were randomly assigned to 16 weeks of chemotherapy alone (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      plus short-term infusional",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      -modulated FU) versus 12 weeks of the same chemotherapy regimen followed by low-dose RT concurrent with cisplatin and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ; both groups underwent subsequent surgical resection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/63\">",
"       63",
"      </a>",
"      ]. The pathologic complete response (pCR) rate was significantly higher after induction chemotherapy followed by chemoradiotherapy, and there was a nonsignificant trend towards better median and three-year survival (47 versus 28 percent, p = 0.07) in this group as well. Whether these results can be extrapolated to SCC of the thoracic esophagus is uncertain. This trial and the implication of its findings for treatment of EGJ cancers are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/51/39738?source=see_link&amp;anchor=H3447368#H3447368\">",
"       \"Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas\", section on 'German POET trial'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although early results from many trials evaluating intensified chemotherapy during RT are encouraging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/66-71\">",
"     66-71",
"    </a>",
"    ], whether the added toxicity of any of these approaches is counterbalanced by substantial survival gains is unclear. Phase III trials are needed to confirm the benefit of these more toxic approaches over concurrent",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"      cisplatin",
"     </a>",
"     /FU.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Necessity for surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The necessity of resection in patients undergoing chemoradiotherapy is controversial. A survival benefit for post-chemoradiotherapy esophagectomy has been suggested in national surveys of patients with thoracic adenocarcinoma or squamous cell cancer (SCC) who were treated in the 1990s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/72-74\">",
"     72-74",
"    </a>",
"    ] and in an analyses of data from a Surveillance, Epidemiology and End Results (SEER) regional database of patients with esophageal cancer who were treated between 1988 and 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/75\">",
"     75",
"    </a>",
"    ]. However, others have questioned the necessity of surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contemporary series, definitive chemoradiotherapy provides long-term survival in up to 27 percent of patients with SCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/4,36,76,77\">",
"     4,36,76,77",
"    </a>",
"    ], a result that is not dissimilar to that achieved with preoperative chemoradiotherapy followed by surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/19,39,43\">",
"     19,39,43",
"    </a>",
"    ], neoadjuvant chemotherapy and surgery (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Neoadjuvant chemotherapy'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/6,78\">",
"     6,78",
"    </a>",
"    ], and surgery alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/6,21\">",
"     6,21",
"    </a>",
"    ]. Nearly all reports note a higher rate of locally",
"    <span class=\"nowrap\">",
"     persistent/recurrent",
"    </span>",
"    disease when surgery is not a component of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/4,77\">",
"     4,77",
"    </a>",
"    ]. In general, there is a lack of data on nonsurgical management for patients with adenocarcinoma, and at least some retrospective series suggest inferior outcomes in this group with nonsurgical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least two randomized trials directly comparing chemoradiotherapy alone to chemoradiotherapy followed by surgery have failed to demonstrate better survival, although both show better locoregional control and a lesser need for palliative procedures when surgery is a component of multimodality treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. The patient populations in both were either exclusively or predominantly SCC:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 172 patients (all with esophageal SCC) were randomly assigned to three cycles of induction 5-FU,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      followed by concomitant chemoradiotherapy (cisplatin plus etoposide on days 2 and 8 only, and 40 Gy external beam RT) and then resection, or the same chemotherapy followed by concomitant chemoradiotherapy (chemotherapy on days 2 and 8 only) with an additional 20 Gy of RT added instead of surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/80\">",
"       80",
"      </a>",
"      ]. Treatment-related mortality was higher in the trimodality arm (12.8 versus 3.5 percent). The surgically treated patients had significantly better local control (two-year local progression-free survival 64 versus 41 percent), but this did not translate into significantly better overall survival at three (31 versus 24 percent), five (28 versus 17 percent), or ten years (19 versus 12 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/82\">",
"       82",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Of note, in comparison to other trials using concomitant chemoradiotherapy alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/4\">",
"       4",
"      </a>",
"      ] or followed by surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/39\">",
"       39",
"      </a>",
"      ], RT doses and the intensity of chemotherapy were lower in this study. This may in part explain the lower survival rate in the nonsurgically treated patients, when compared to the results of RTOG 85-01 (see",
"      <a class=\"local\" href=\"#H8\">",
"       'RTOG 85-01'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      In the French trial FFCD 9102, 444 patients with potentially resectable T3, N0-1, M0 esophageal SCC (89 percent) or adenocarcinoma (11 percent) received induction chemoradiotherapy with either protracted (46 Gy in 4.5 weeks) or split course (2 X 15 Gy, days 1 to 5 and 22 to 26) RT concurrent with two courses of FU and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/81\">",
"       81",
"      </a>",
"      ]. Patients with at least a partial response and who had no contraindication to surgery (n = 259) were then randomly assigned to continue chemoradiotherapy (three more cycles of chemotherapy with either 30 Gy [protracted] or 15 Gy [split course] RT) or to undergo surgery.",
"      <br/>",
"      <br/>",
"      At a median follow-up of 47 months, the surgically treated patients had similar two-year (34 versus 40 percent) and median survival (17.7 versus 19.3 months) as compared to those assigned to continue chemoradiotherapy. Surgically treated patients had significantly lower rates of locoregional recurrence (34 versus 43 percent) and were significantly less likely to require palliative intervention for dysphagia (24 versus 46 percent). There were no differences in longitudinal quality of life among survivors with two years of follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some of the only data on nonsurgical management of adenocarcinoma come from a retrospective analysis of 239 patients treated with definitive chemoradiotherapy at MD Anderson for unresectable esophageal cancer, 181 of whom had adenocarcinoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/84\">",
"       84",
"      </a>",
"      ]. RT was planned and delivered using modern techniques (four-dimensional CT and intensity-modulated RT), and a moderate-dose (50.4 Gy in 28 fractions) was combined with chemotherapy. The majority of patients had T3 (81 percent), N1 (67 percent), and M0 (79 percent) disease. Nearly all (99 percent) received concurrent chemotherapy, and 46 percent also received induction chemotherapy. At a median follow-up of 44 months, 119 (50 percent) had experienced a local recurrence, 107 of whom failed within the gross tumor volume while 116 (48 percent) encountered distant failure and 74 (31 percent) had no evidence of disease at last follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these data suggest that patients who undergo surgery after chemoradiotherapy appear to have better locoregional control and similar quality of life. Thus, inclusion of surgery remains the preferred treatment approach for clinically resectable esophageal cancer, particularly for adenocarcinoma since there are few data on nonsurgical management, and the rate of pathologic complete response is relatively low as compared to SCC.",
"   </p>",
"   <p>",
"    For patients with SCC who have an endoscopic complete response, nonoperative management is an option balancing the risks of surgical mortality versus improved locoregional control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20504361\">",
"    <span class=\"h4\">",
"     Utility of postinduction therapy PET scans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postinduction therapy FDG PET provides information about metabolic response in the primary tumor that may be clinically useful for selection of subsequent therapy.",
"   </p>",
"   <p>",
"    In particular, some retrospective data suggest that post-chemoradiotherapy FDG-PET scanning may serve to identify those patients for whom surgery might be avoided. One series included 105 patients with stage I to IVA esophageal cancer (75 percent adenocarcinoma) who were evaluable for a post-chemoradiotherapy PET response, 50 of whom received chemoradiotherapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/85\">",
"     85",
"    </a>",
"    ]. In this cohort, those whose PET response was characterized by a posttreatment standard uptake value (SUV) &le;3 in the tumor (n = 19, 38 percent) had an excellent outcome without resection (two-year overall survival 71 versus 11 percent for those with a posttreatment tumoral SUV &ge;3.1; the corresponding two-year rates of freedom from local failure were 75 versus 28 percent). In contrast, those patients undergoing trimodality therapy (n = 55) showed no difference in outcome according to the post-chemoradiotherapy PET findings, probably because those patients who had residual disease underwent resection.",
"   </p>",
"   <p>",
"    However, others have failed to find a correlation between the postchemoradiotherapy SUV on PET and pathologic responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/86\">",
"     86",
"    </a>",
"    ]. Thus, these data need to be confirmed and validated in a prospective trial before PET-directed therapy for esophageal cancer can be considered a standard approach. Furthermore, the best method to quantify FDG PET for clinical use in esophageal cancer remains to be determined.",
"   </p>",
"   <p>",
"    The main use of PET in esophageal cancer may be to recognize which patients are not responding to induction chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. Tailoring treatment based upon postinduction chemotherapy PET scanning is being directly studied in CALGB 80302 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/89\">",
"     89",
"    </a>",
"    ]. These and other data on the utility of postinduction therapy PET scans are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/51/39738?source=see_link&amp;anchor=H5353223#H5353223\">",
"     \"Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas\", section on 'Use of PET and PET-CT during treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Neoadjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple randomized trials have evaluated the benefit of chemotherapy administered prior to resection in patients with esophageal cancer limited to the primary and regional nodes by clinical assessment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/6,50,78,90-93\">",
"     6,50,78,90-93",
"    </a>",
"    ]. Four trials with a surgery alone control arm are negative, including the US Intergroup 0113 trial, [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/6,50,90,94\">",
"     6,50,90,94",
"    </a>",
"    ] while three others (the MRC OE2 trial, the UK MAGIC trial, and a preliminary report of the French",
"    <span class=\"nowrap\">",
"     FNLCC/FFCD",
"    </span>",
"    trial), demonstrate a survival benefit compared to resection alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/78,91,92,95\">",
"     78,91,92,95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Meta-analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;A survival benefit for neoadjuvant chemotherapy relative to surgery alone was shown in a year 2011 meta-analysis that included nine randomized comparisons of neoadjuvant chemotherapy versus surgery alone for esophageal or EGJ cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/48\">",
"     48",
"    </a>",
"    ]. The hazard ratio (HR) for all-cause mortality for neoadjuvant chemotherapy was 0.87 (95% CI 0.70-0.88), and this translated into an absolute survival benefit at two years of 5.1 percent and a number needed to treat to prevent one death of 19. The potential benefit of neoadjuvant therapy was not offset by a higher postoperative mortality (in-hospital or 30-day postoperative death). Subgroup analysis by histologic type, for those studies where histology data were available gave an HR for SCC of 0.80 (95% CI 0.68-0.93), while for adenocarcinomas the HR was 0.75 (95% CI 0.59-0.95). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Neoadjuvant chemotherapy versus chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy was directly compared to chemoradiotherapy in a randomized phase II Australian trial involving 75 patients with adenocarcinoma of the esophagus or EGJ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/96\">",
"     96",
"    </a>",
"    ]. Although the histopathologic response rate and rate of margin-negative resections favored chemoradiotherapy, median overall survival was not significantly better (32 versus 29 months).",
"   </p>",
"   <p>",
"    The only phase III trial to directly compare induction chemoradiotherapy versus chemotherapy was the multicenter German POET trial, in which 126 patients with EGJ adenocarcinoma were randomly assigned to 16 weeks of chemotherapy alone (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus short-term infusional FU plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    ) versus 12 weeks of the same chemotherapy regimen followed by low-dose RT concurrent with cisplatin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ; both groups underwent subsequent surgical resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/63\">",
"     63",
"    </a>",
"    ]. The pathologic complete response (pCR) rate was significantly higher after induction chemotherapy followed by chemoradiotherapy (16 versus 2 percent), and there was a nonsignificant trend towards better median and three-year survival in this group as well (47 versus 28 percent, p = 0.07). These data, which are discussed in more detail elsewhere, support the view that chemoradiotherapy is a preferred strategy rather than induction chemotherapy alone for patients with EGJ adenocarcinomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/51/39738?source=see_link&amp;anchor=H3447368#H3447368\">",
"     \"Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas\", section on 'German POET trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of note, both of these trials were closed prematurely, and therefore, underpowered to show a survival advantage; neither enrolled patients with SCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3087792\">",
"    <span class=\"h3\">",
"     Meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;These two trials were subjected to a meta-analysis, and the HR for all-cause mortality was 0.77 in favor of chemoradiotherapy, but this was not statistically significant (95% CI 0.53-1.12) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21960746\">",
"    <span class=\"h2\">",
"     Neoadjuvant chemotherapy versus postoperative chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The superiority of neoadjuvant as compared to postoperative adjuvant chemotherapy was shown in a Japanese trial (JCOG9907) in which 330 patients with clinical stage II or III SCC of the thoracic esophagus were randomly assigned to surgery preceded or followed by two 21-day courses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (80",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1) plus infusional FU (800",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily for five days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/93\">",
"     93",
"    </a>",
"    ]. Five-year overall survival was significantly higher in the group receiving preoperative chemotherapy (55 versus 43 percent, p = 0.04).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Impact of preoperative treatment on local control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most trials focus upon survival as a primary endpoint, local-regional control is also important when selecting among treatment options. Local failures can be defined as recurrent local disease following margin-negative esophagectomy or positive resection margins. Using this definition, the frequency of local failure appears to be higher in trials in which patients were treated with surgery alone or chemoradiotherapy alone as compared to those receiving chemoradiotherapy followed by surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/6,21,39,77,97\">",
"     6,21,39,77,97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, in the Michigan study, described above, the rate of local failure as the first site of failure was significantly lower in those randomized to combined modality therapy compared to surgery alone (19 versus 42 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/39\">",
"     39",
"    </a>",
"    ]. In the previously described meta-analysis of trials comparing preoperative chemoradiotherapy to surgery alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/97\">",
"     97",
"    </a>",
"    ], the odds ratio for local-regional recurrences was significantly lower with preoperative therapy (OR for local recurrence 0.38, 95% CI 0.23-0.63). (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Concurrent chemoradiotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Whether local recurrence rates are lower in patients treated with neoadjuvant chemotherapy as compared to surgery alone is uncertain. In the MAGIC trial, local failure was confirmed before death in fewer patients in the chemotherapy group as compared to surgery alone (14 versus 20 percent), but the p value for the comparison was not reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/91\">",
"     91",
"    </a>",
"    ]. In the MRC trial, the local failure rates were nearly identical in the chemotherapy and surgery groups (12 and 11 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/78\">",
"     78",
"    </a>",
"    ]. The meta-analysis of preoperative chemotherapy versus surgery alone did not address the issue of locoregional control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/98\">",
"     98",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Meta-analyses'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Technique for preoperative RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of response of a tumor and normal",
"    <span class=\"nowrap\">",
"     tissues/organs",
"    </span>",
"    to radiation depends upon several radiotherapeutic factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/99-101\">",
"     99-101",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fraction size (standard fraction size, 1.8 Gy to 2.0 Gy) and interfractional intervals (standard interval, 24 hours)",
"     </li>",
"     <li>",
"      Total dose (standard preoperative dose in once daily schedule, 45 to 50.4 Gy)",
"     </li>",
"     <li>",
"      Duration of treatment (5 to 5.6 weeks for standard fractionation, without a rest during treatment)",
"     </li>",
"     <li>",
"      The arrangement of radiation portals in a manner that achieves the maximum dose differential between tumor and adjacent vital organs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Significant deviations from standard techniques should be avoided in a potentially curative setting. Fraction sizes that are larger than 2.5 Gy, treatment breaks of longer than one week, split-course fractionation schedules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/77\">",
"     77",
"    </a>",
"    ], and suboptimal radiation plans with a potential for increased risk of injury to the lung, heart and spinal cord should be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     3D conformal RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three-dimensional conformal RT (3D-CRT) is recommended for the best possible coverage of the target volume while protecting the surrounding normal organs from excess RT dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Target volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;The target volume consists of gross tumor volume (GTV) with a margin of clinically uninvolved tissue (clinical target volume, or CTV). The CTV should include 4 to 5 cm margins beyond the radiographic tumor extent (GTV) in the cephalad-caudad direction and 2 to 2.5 cm beyond the radial border of GTV (defined by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    esophagogram or CT scan). For lesions of the lower third of the esophagus and gastroesophageal junction (GEJ), the caudal extension CTV beyond GTV includes a 3 to 4 cm margin of gastric cardia below the lower border of GTV. CTV for regional lymph nodes includes the celiac, gastric, and gastrohepatic Iymph node groups for primary tumors at the GE junction. For primary tumors involving the upper two-thirds of the thoracic or the cervical esophagus, CTV includes both supraclavicular regions. It is necessary to add another 0.7 cm beyond CTV as the PTV (planning target volume) in order to compensate for daily set-up error and respiratory tumor motion.",
"   </p>",
"   <p>",
"    Esophageal cancers that are located at the GE junction can have a significant degree of tumor motion associated with respiration. We reported peak-to-peak motion of the primary tumor in 10 patients (nine near the GE junction with their involved lymph nodes at the celiac region) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/101\">",
"     101",
"    </a>",
"    ]. The peak-to-peak tumor motion in craniocaudal directions ranged from 0.6 cm to 4.8 cm for the primary tumor and from 1.2 cm to 4.4 cm for the involved lymph nodes. In order to avoid geographic miss in some of these patients when using 3D CRT, four-dimensional (4D) CT treatment planning and delivery of 3D CRT according to the tumor characteristics of individual patients has a significant advantage for optimum coverage of the target volume over 3D-CRT planned with the conventional helical CT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Optimal dose and fractionation schedules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor size and radiation dose are important considerations for local-regional tumor control. Radiation therapy with curative intent requires a total dose of 60 to 66.6 Gy in 30 to 37 daily fractions using 1.8 to 2.0 Gy daily fractions, five fractions per week. Small daily fractions (ie, 1.8 to 2.0 Gy instead of 2.5 to 3.0 Gy) reduce the likelihood of late toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/99,100\">",
"     99,100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal radiation dose for preoperative chemoradiotherapy regimens is not defined, although a total dose of 41.4 to 50.4 Gy administered in daily 1.8 Gy fractions, five days per week, produces reasonable results with acceptable toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/4,47,76,102\">",
"     4,47,76,102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Altered fractionation schedules such as accelerated schedules (45 Gy in 30 fractions over three weeks using twice daily 1.5 Gy fractions) or hybrid schedules using twice daily radiation during chemotherapy and once daily treatment between chemotherapy cycles (45 Gy in 25 fractions over five weeks to CTV, and 58.5 Gy in 34 fractions over five weeks to GTV, respectively) are tolerable, with encouraging tumor response, high pathologic CR rates, and survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/39,103\">",
"     39,103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients judged inoperable because of either poor general condition or the presence of distant metastases can be treated by rapid fractionation schedules. A total dose of 40 to 45 Gy at 2.5 Gy daily fractions five days a week is a reasonable schedule for patients who require palliation of esophageal obstruction.",
"   </p>",
"   <p>",
"    3D CRT uses four to six beams to conform the distribution of radiation dose to the GTV and PTV, while the surrounding normal structures are spared from excessive radiation dose, to the greatest extent possible. 3D CRT plan provides a dose-volume-histogram for GTV and PTV as well as for normal organs at risk for complications. Thus, it is feasible to formulate a radiation dose schedule for the desired level of tumor control probability that is balanced with an acceptable level of toxicities.",
"   </p>",
"   <p>",
"    Intensity-modulated radiation therapy (IMRT) is an advanced form of 3D CRT. IMRT uses inverse treatment planning to generate optimum treatment plan. IMRT uses dynamic multileaf collimators to conform the radiation beam to the shape of the tumor from any angle, while protecting normal adjacent tissue as much as possible. It may be expected (though not yet proven) that treatment with IMRT will result in fewer side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/104-106\">",
"     104-106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H484837\">",
"    <span class=\"h2\">",
"     Postoperative adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the data presented above, many patients with esophageal or esophagogastric junction (EGJ) cancer are offered induction therapy with chemotherapy or chemotherapy plus RT prior to attempted surgical resection. Although this is a preferred approach for patients who present with clinically node-positive or",
"    <span class=\"nowrap\">",
"     T3/4",
"    </span>",
"    disease, some patients will undergo surgery initially. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Chemoradiotherapy'",
"    </a>",
"    above.) For patients who are found to have node-positive or T4 disease after undergoing surgery alone, the addition of postoperative adjuvant therapy (chemotherapy with or without RT) is reasonable in an effort to improve outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/107,108\">",
"     107,108",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H484972\">",
"    <span class=\"h3\">",
"     Chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with a node-positive adenocarcinoma of the EGJ, postoperative chemoradiotherapy is a standard approach, at least in the United States, based upon results from the US Intergroup trial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/51/39738?source=see_link&amp;anchor=H1035777#H1035777\">",
"     \"Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas\", section on 'Adjuvant chemoradiotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For other patients, particularly those with an esophageal squamous cell cancer, the optimal approach is uncertain. Some uncontrolled trials and retrospective comparisons of patients treated with and without chemoradiotherapy suggest potential benefit for postoperative chemoradiotherapy. However, others do not, and there are no randomized trials proving benefit as compared to surgery alone:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective report, outcomes of 38 patients with node-positive disease after esophagectomy alone who received postoperative chemoradiotherapy (concurrent or sequential RT plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      and FU with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      ) were compared to 28 similar patients who did not receive further therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/109\">",
"       109",
"      </a>",
"      ]. Local recurrence rates were lower in the group receiving postoperative therapy (35 versus 13 percent), and the median overall survival was longer (48 versus 14 months).",
"     </li>",
"     <li>",
"      Mature data from a prospective phase II uncontrolled trial also support benefit for adjuvant chemoradiotherapy in this setting. In this trial, 50 patients with locally advanced esophageal cancer (90 percent T3, 81 percent node-positive, 13 percent with extraregional nodal metastases) received chemoradiotherapy (RT 50.4 to 59.4 Gy plus concurrent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      and FU) after esophagectomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/110\">",
"       110",
"      </a>",
"      ]. At a median follow-up of 47 months, four year projected survival was 51 percent, a rate that is far higher than might be expected for this relatively poor prognosis cohort.",
"     </li>",
"     <li>",
"      The contribution of RT to these results has been questioned. A lack of benefit from RT was suggested by a randomized trial comparing postoperative chemotherapy (five weeks of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      plus FU) alone versus the same chemotherapy regimen with RT (50 Gy over five weeks) in 45 patients undergoing potentially curative resection for squamous cell cancer of the thoracic esophagus who did not receive preoperative therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/111\">",
"       111",
"      </a>",
"      ]. There was no significant benefit from the addition of RT to chemotherapy in terms of five-year survival (50 versus 38 percent), and locoregional control rates were also not better in this group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H484979\">",
"    <span class=\"h3\">",
"     Chemotherapy alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with esophageal cancer who have not received preoperative chemotherapy or chemoradiotherapy, postoperative chemotherapy alone may be beneficial, although proof of a survival benefit from randomized trials with a surgery alone control group is absent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benefit for adjuvant chemotherapy alone was suggested in an uncontrolled trial conducted by the Eastern Cooperative Oncology Group that included patients with distal esophageal (n = 9), EG junction (n = 34) or gastric cardia (n = 12) tumors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/112\">",
"       112",
"      </a>",
"      ]. Eligible patients had either T2N1-2 or",
"      <span class=\"nowrap\">",
"       T3/4",
"      </span>",
"      disease that was completely resected with negative margins; 49 (89 percent) were node-positive. Treatment consisted of four three-week cycles of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      (175",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      followed by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ).",
"      </span>",
"      With a median follow-up of four years, the two and three-year survival rates were 60 and 44 percent, respectively. The lack of a surgery alone control group precludes interpretation of these data.",
"     </li>",
"     <li>",
"      The only randomized trial to compare surgery alone versus surgery followed by adjuvant chemotherapy (two courses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      80",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1 and FU 800",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily for five days) included 242 patients with esophageal squamous cell cancer recruited from 17 Japanese institutions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/113\">",
"       113",
"      </a>",
"      ]. The five-year disease-free survival rate (the primary endpoint) was significantly better with chemotherapy (55 versus 45 percent), but overall survival was not significantly different (61 versus 52 percent). The short duration of adjuvant chemotherapy, and the fact that 25 percent of the patients in the chemotherapy group did not receive both full courses of therapy may have compromised the ability to document a survival difference.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H484986\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with completely resected node-positive esophageal cancer who have not received neoadjuvant therapy, we typically recommend some form of postoperative therapy. It is difficult to come to any conclusions as to whether there are specific advantages for adjuvant chemoradiotherapy over chemotherapy alone. In our view, either approach is reasonable. Further confirmatory trials, particularly randomized trials, are necessary before specific recommendations can be made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H493565\">",
"    <span class=\"h1\">",
"     POSTTREATMENT CANCER SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of recurrences develop within one year. In a series of 590 patients who underwent esophagectomy for adenocarcinoma, the peak interval for recurrence after esophagectomy alone was six to nine months, and more than 90 percent of the disease recurrences occurred by three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/114\">",
"     114",
"    </a>",
"    ]. In contrast, among patients treated with neoadjuvant chemoradiotherapy, the peak time frame for recurrence was the first three months, and &gt;90 percent of recurrences were evident by 21 months. The pattern of recurrence was distant, locoregional, or both in 60, 30, and 10 percent of patients, respectively, and did not differ in patients treated with induction chemoradiotherapy versus surgery alone.",
"   </p>",
"   <p>",
"    There are no randomized trials to guide the postoperative surveillance strategy, and no data that demonstrate improvement in quality of life or longevity from earlier detection of asymptomatic recurrences. Nevertheless, consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) suggest the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/115\">",
"     115",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History and physical examination every three to six months for one to three years, then every six months for years four and five, then annually",
"     </li>",
"     <li>",
"      CBC and chemistry profile, as clinically indicated",
"     </li>",
"     <li>",
"      Radiologic imaging and upper GI endoscopy, as clinically indicated",
"     </li>",
"     <li>",
"      Dilation for anastomotic stenosis",
"     </li>",
"     <li>",
"      Nutritional counseling",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At our institution, we perform history, physical examination, and targeted blood work (for a symptomatic patient, or if there was a serum tumor marker that was elevated preoperatively) every four months for the first three years and also perform restaging CT scans of the chest and abdomen at four month intervals. We do not carry out surveillance endoscopy unless there was a preoperative history of Barrett's esophagus, a questionable margin at the time of surgery, or if the patient has a recalcitrant stricture that is worrisome for an occult local recurrence.",
"   </p>",
"   <p>",
"    When planning the posttreatment surveillance strategy, care should be taken to limit the number of CT scans, particularly in younger individuals, given concerns about radiation exposure and the risk for second malignancies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H493619\">",
"    <span class=\"h1\">",
"     CERVICAL ESOPHAGUS TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Squamous cell cancer (SCC) of the cervical esophagus presents a unique management situation. If surgery is performed, it usually requires removal of portions of the pharynx, the larynx, the thyroid gland, and portions of the proximal esophagus. In addition, radical neck dissections are usually carried out; as such, the management is more closely related to SCC of the head and neck than for malignancies involving the more distal portions of the esophagus. In general, radiation therapy combined with chemotherapy is preferred over surgery for these patients since survival appears to be the same and major morbidity is avoided in most. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/30/34282?source=see_link&amp;anchor=H7377428#H7377428\">",
"     \"Surgical oncologic principles for management of resectable esophageal cancer\", section on 'Cervical esophageal cancer resection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30106?source=see_link&amp;anchor=H10737259#H10737259\">",
"     \"Management of locally advanced unresectable esophageal cancer\", section on 'Cervical esophageal tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/17/9491?source=see_link\">",
"       \"Patient information: Esophageal cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of local-regional cancer of the esophagus and esophagogastric junction (EGJ) has undergone a major evolution over the past 15 years. The majority of patients now undergo some form of combined modality therapy rather than local therapy alone. However, the optimal management of these patients remains controversial. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two major histologies of esophageal cancer: squamous cell cancer (SCC) and adenocarcinoma. Although most clinical studies have not differentiated between these two tumor entities, an increasing amount of evidence supports the view that they differ in terms of their pathogenesis, epidemiology, tumor biology, and prognosis. In recognition of these differences, the 2010 edition of the TNM staging criteria provides separate stage groupings for SCC and adenocarcinomas of the esophagus and EGJ (",
"      <a class=\"graphic graphic_table graphicRef62895 \" href=\"mobipreview.htm?13/38/13934\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef52078 \" href=\"mobipreview.htm?4/24/4494\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/7\">",
"       7",
"      </a>",
"      ]. However, it remains unclear whether and how histology should be used to select the treatment approach, and largely due to the lack of data on the impact of histology on treatment outcomes, the approach tends to be similar for both histologies.",
"      <br/>",
"      <br/>",
"      At least two randomized trials directly comparing chemoradiotherapy alone to chemoradiotherapy followed by surgery have failed to demonstrate better survival, although both show better locoregional control and a lesser need for palliative procedures when surgery is a component of multimodality treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/31/39418/abstract/80,81\">",
"       80,81",
"      </a>",
"      ]. The patient populations in both were either exclusively or predominantly SCC.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8182417\">",
"    <span class=\"h2\">",
"     Thoracic esophageal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following conclusions regarding therapy for thoracic esophageal cancers can be derived from phase III studies comparing definitive chemoradiotherapy to radiotherapy alone, and preoperative chemoradiotherapy or preoperative chemotherapy to surgery alone for patients with esophageal or GEJ cancer that is localized to the primary site and regional nodes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While definitive chemoradiotherapy is a potentially curative option for SCC, there is a high rate of locally",
"      <span class=\"nowrap\">",
"       persistent/recurrent",
"      </span>",
"      disease after chemoradiotherapy alone, and a lack of data on nonsurgical management of patients with adenocarcinoma, who have a low rate of pathologic complete response after chemoradiotherapy. Thus, inclusion of surgery is preferred for clinically resectable esophageal cancer, particularly for adenocarcinoma. For patients with SCC who have an endoscopically-documented complete response, nonoperative management is an option balancing the risks of surgical mortality versus improved locoregional control. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Necessity for surgery'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Several trials and meta-analyses support the view that a concurrent trimodality approach (concomitant chemoradiotherapy followed by surgery) provides a survival benefit compared to surgery alone. Further, local control appears to be better with preoperative chemoradiotherapy compared to surgery alone. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Concurrent chemoradiotherapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Induction chemotherapy without RT also provides a significant survival benefit over surgery alone, and this approach has been adopted in the United Kingdom based upon the results of several neoadjuvant trials, including the MAGIC trial. However, whether these results can be extrapolated to the setting of esophageal SCCs is uncertain. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Meta-analyses'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Furthermore, local failure rates may be lower in patients treated with chemoradiotherapy followed by surgery compared to those receiving either chemotherapy followed by surgery or surgery alone. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Impact of preoperative treatment on local control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As a result of these issues, we recommend combined modality therapy rather than surgery alone for patients with T2-3N0 stage I, and all patients with stages IIA, IIB, and III thoracic esophageal cancer regardless of histology (",
"      <a class=\"graphic graphic_table graphicRef62895 \" href=\"mobipreview.htm?13/38/13934\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef52078 \" href=\"mobipreview.htm?4/24/4494\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For these patients, we suggest concurrent chemoradiotherapy instead of chemotherapy alone for neoadjuvant therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Definitive chemoradiotherapy is a reasonable approach for patients who are not surgical candidates.",
"      <br/>",
"      <br/>",
"      The benefit of preoperative chemoradiotherapy for patients with T1N0 esophageal or EGJ adenocarcinoma or SCC is less clear. We recommend surgery alone in these patients (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Definitive chemoradiotherapy is a reasonable approach for patients who are not surgical candidates.",
"     </li>",
"     <li>",
"      Although the optimal type, dose, combination, and schedule of drugs has not been definitively established, we suggest the low-dose weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      regimen (",
"      <a class=\"graphic graphic_table graphicRef68266 \" href=\"mobipreview.htm?2/49/2846\">",
"       table 4",
"      </a>",
"      ) as was used in the Dutch CROSS trial rather than two courses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      plus 5-FU as was used in CALGB 9781 (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4965589\">",
"       'CROSS trial'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4965660\">",
"       'CALGB 9781'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43378?source=see_link\">",
"       \"Treatment protocols for esophagogastric cancer\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Issues related to carboplatin dosing (ie, estimation of GFR, appropriate weight to use in the calculation of drug dose according to the Calvert formula) are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=see_link&amp;anchor=H7#H7\">",
"       \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'AUC dose calculation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The optimal dose-fractionation RT schedule for concurrent chemoradiotherapy regimens remains to be determined. However, 3-D conformal techniques should be used for modern treatment planning to minimize toxicities to adjacent vital organs (ie, heart, lung, spinal cord, or liver). Even though the Dutch CROSS trial used a lower dose (41.4 Gy), the standard dose of RT for patients treated with concurrent chemotherapy remains 50.4 Gy administered in 28 daily fractions, as was used in CALGB 9781 and RTOG 85-01. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Optimal dose and fractionation schedules'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4965589\">",
"       'CROSS trial'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4965660\">",
"       'CALGB 9781'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with completely resected node-positive esophageal cancer who have not received neoadjuvant therapy, we suggest postoperative adjuvant therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Chemotherapy alone or chemoradiotherapy are both reasonable options. (See",
"      <a class=\"local\" href=\"#H484837\">",
"       'Postoperative adjuvant therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8182762\">",
"    <span class=\"h2\">",
"     EGJ cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most clinicians now treat esophagogastric junction (EGJ) and proximal gastric (ie, cardia, (",
"    <a class=\"graphic graphic_figure graphicRef56689 \" href=\"mobipreview.htm?40/59/41907\">",
"     figure 1",
"    </a>",
"    )) cancers as esophageal cancers with preoperative chemoradiotherapy. However, these tumors have been included in many of the trials examining the benefit of adjuvant and neoadjuvant chemotherapy for gastric cancer, and institutional practice varies. The therapeutic approach to tumors of the EGJ is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/51/39738?source=see_link\">",
"     \"Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8182671\">",
"    <span class=\"h2\">",
"     Cervical esophageal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of carcinoma arising in the cervical esophagus is more closely related to SCC of the head and neck than for malignancies involving the more distal portions of the esophagus. In general, radiation combined with chemotherapy is preferred over surgery for these patients since survival appears to be the same, and major morbidity is avoided in most. (See",
"    <a class=\"local\" href=\"#H493619\">",
"     'Cervical esophagus tumors'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/2\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/3\">",
"      Daly JM, Karnell LH, Menck HR. National Cancer Data Base report on esophageal carcinoma. Cancer 1996; 78:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/4\">",
"      Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/5\">",
"      Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999; 281:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/6\">",
"      Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339:1979.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.103.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/8\">",
"      Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol 2007; 17:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/9\">",
"      Mariette C, Finzi L, Piessen G, et al. Esophageal carcinoma: prognostic differences between squamous cell carcinoma and adenocarcinoma. World J Surg 2005; 29:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/10\">",
"      Alexandrou A, Davis PA, Law S, et al. Squamous cell carcinoma and adenocarcinoma of the lower third of the esophagus and gastric cardia: similarities and differences. Dis Esophagus 2002; 15:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/11\">",
"      Kuwano H, Saeki H, Kawaguchi H, et al. Proliferative activity of cancer cells in front and center areas of carcinoma in situ and invasive sites of esophageal squamous-cell carcinoma. Int J Cancer 1998; 78:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/12\">",
"      Koppert LB, Janssen-Heijnen ML, Louwman MW, et al. Comparison of comorbidity prevalence in oesophageal and gastric carcinoma patients: a population-based study. Eur J Gastroenterol Hepatol 2004; 16:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/13\">",
"      Siewert JR, Feith M, Stein HJ. Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. J Surg Oncol 2005; 90:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/14\">",
"      Lieberman MD, Shriver CD, Bleckner S, Burt M. Carcinoma of the esophagus. Prognostic significance of histologic type. J Thorac Cardiovasc Surg 1995; 109:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/15\">",
"      Siewert JR, Stein HJ, Feith M, et al. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg 2001; 234:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/16\">",
"      H&ouml;lscher AH, Bollschweiler E, Schneider PM, Siewert JR. Prognosis of early esophageal cancer. Comparison between adeno- and squamous cell carcinoma. Cancer 1995; 76:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/17\">",
"      Bollschweiler E, Metzger R, Drebber U, et al. Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol 2009; 20:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/18\">",
"      Gertler R, Stein HJ, Langer R, et al. Long-term Outcome of 2920 Patients With Cancers of the Esophagus and Esophagogastric Junction: Evaluation of the New Union Internationale Contre le Cancer/American Joint Cancer Committee Staging System. Ann Surg 2011; 253:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/19\">",
"      O'Reilly S, Forastiere AA. Is surgery necessary with multimodality treatment of oesophageal cancer. Ann Oncol 1995; 6:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/20\">",
"      Coia LR. Esophageal cancer: is esophagectomy necessary? Oncology (Williston Park) 1989; 3:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/21\">",
"      Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997; 337:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/22\">",
"      Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002; 347:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/23\">",
"      Altorki N, Kent M, Ferrara C, Port J. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg 2002; 236:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/24\">",
"      Orringer MB, Marshall B, Iannettoni MD. Transhiatal esophagectomy: clinical experience and refinements. Ann Surg 1999; 230:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/25\">",
"      Rajagopalan J, Triadafilopoulos G. Ring(s)-related esophageal meat bolus impaction: biopsy first, dilate later. Dis Esophagus 2009; 22:E14.",
"     </a>",
"    </li>",
"    <li>",
"     Choi NC. The role of radiation therapy in the management of malignant neoplasms of the esophagus. In: Current Therapy in Cardiothoracic Surgery, Grillo HC, Austen WG, Wilkins EW Jr (Eds), BC Decker Inc, Toronto 1989. p.197.",
"    </li>",
"    <li>",
"     Choi NC. Carcinoma of the esophagus. In: Clinical Radiation Oncology: Indications, Techniques, Results, Wang CC (Ed), Wiley-Liss, New York 2000. p.333.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/28\">",
"      Sykes AJ, Burt PA, Slevin NJ, et al. Radical radiotherapy for carcinoma of the oesophagus: an effective alternative to surgery. Radiother Oncol 1998; 48:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/29\">",
"      Earlam R, Cunha-Melo JR. Oesophogeal squamous cell carcinoms: II. A critical view of radiotherapy. Br J Surg 1980; 67:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/30\">",
"      Shioyama Y, Nakamura K, Sasaki T, et al. Clinical results of radiation therapy for stage I esophageal cancer: a single institutional experience. Am J Clin Oncol 2005; 28:75.",
"     </a>",
"    </li>",
"    <li>",
"     Yu J, Ren R, Sun X, et al. A randomized clinical study of surgery versus radiotherapy in the treatment of resectable esophageal cancer (abstract). J Clin Oncol 2006; 24:181s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/32\">",
"      McGinn CJ, Kinsella TJ. The experimental and clinical rationale for the use of S-phase-specific radiosensitizers to overcome tumor cell repopulation. Semin Oncol 1992; 19:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/33\">",
"      Forastiere AA. Treatment of locoregional esophageal cancer. Semin Oncol 1992; 19:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/34\">",
"      Herscher LL, Cook JA, Pacelli R, et al. Principles of chemoradiation: theoretical and practical considerations. Oncology (Williston Park) 1999; 13:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/35\">",
"      Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev 2001; :CD002092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/36\">",
"      Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/37\">",
"      Tougeron D, Di Fiore F, Thureau S, et al. Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer. Br J Cancer 2008; 99:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/38\">",
"      Abrams JA, Buono DL, Strauss J, et al. Esophagectomy compared with chemoradiation for early stage esophageal cancer in the elderly. Cancer 2009; 115:4924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/39\">",
"      Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001; 19:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/40\">",
"      Nygaard K, Hagen S, Hansen HS, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 1992; 16:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/41\">",
"      Le Prise E, Etienne PL, Meunier B, et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994; 73:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/42\">",
"      Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005; 6:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/43\">",
"      Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/44\">",
"      Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26:1086.",
"     </a>",
"    </li>",
"    <li>",
"     Gaast AV, van Hagen P, Hulshof M, et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric cancer: Results from a multinational randomized phase III study (abstract 4004). J Clin Oncol 2010; 28:302s.",
"    </li>",
"    <li>",
"     Mariette C, Seitz JF, Maillard E, et al. Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: Analysis of a randomized controlled phase III trial FFCD 9901 (abstract 4005). J Clin Oncol 2010; 28:302s. file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=74&amp;abstractID=52216 (Accessed on February 19, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/47\">",
"      van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366:2074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/48\">",
"      Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/49\">",
"      Rohatgi PR, Swisher SG, Correa AM, et al. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer 2005; 104:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/50\">",
"      Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001; 91:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/51\">",
"      Kleinberg L, Knisely JP, Heitmiller R, et al. Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2003; 56:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/52\">",
"      Choi N, Park SD, Lynch T, et al. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study. Int J Radiat Oncol Biol Phys 2004; 60:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/53\">",
"      Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 2005; 103:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/54\">",
"      Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005; 23:4330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/55\">",
"      Lagarde SM, ten Kate FJ, Reitsma JB, et al. Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol 2006; 24:4347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/56\">",
"      Rizk NP, Venkatraman E, Bains MS, et al. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol 2007; 25:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/57\">",
"      Rizk NP, Seshan VE, Bains MS, et al. Prognostic factors after combined modality treatment of squamous cell carcinoma of the esophagus. J Thorac Oncol 2007; 2:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/58\">",
"      Kim MK, Kim SB, Ahn JH, et al. Treatment outcome and recursive partitioning analysis-based prognostic factors in patients with esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys 2008; 71:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/59\">",
"      Scheer RV, Fakiris AJ, Johnstone PA. Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer. Int J Radiat Oncol Biol Phys 2011; 80:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/60\">",
"      Ajani JA, Walsh G, Komaki R, et al. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer 2004; 100:2347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/61\">",
"      Swisher SG, Ajani JA, Komaki R, et al. Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 2003; 57:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/62\">",
"      Ajani JA, Komaki R, Putnam JB, et al. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer 2001; 92:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/63\">",
"      Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27:851.",
"     </a>",
"    </li>",
"    <li>",
"     Carstens H, Albertsson M, Friesland S, et al. A randomized trial of chemoradiotherapy versus surgery alone in patients with resectable esophageal cancer (Abstract). J Clin Oncol 2007; 25:205s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/65\">",
"      Pasini F, de Manzoni G, Zanoni A, et al. Neoadjuvant therapy with weekly docetaxel and cisplatin, 5-fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of long-lasting pathological complete response: a phase 2 study. Cancer 2013; 119:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/66\">",
"      Meluch AA, Greco FA, Gray JR, et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J 2003; 9:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/67\">",
"      Khushalani NI, Leichman CG, Proulx G, et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol 2002; 20:2844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/68\">",
"      van de Schoot L, Romme EA, van der Sangen MJ, et al. A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer. Ann Surg Oncol 2008; 15:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/69\">",
"      Jatoi A, Martenson JA, Foster NR, et al. Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044). Am J Clin Oncol 2007; 30:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/70\">",
"      Chiarion-Sileni V, Innocente R, Cavina R, et al. Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer. Cancer Chemother Pharmacol 2009; 63:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/71\">",
"      Conroy T, Yatagh&egrave;ne Y, Etienne PL, et al. Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer. Br J Cancer 2010; 103:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/72\">",
"      Coia LR, Minsky BD, Berkey BA, et al. Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 Patterns of Care Study. J Clin Oncol 2000; 18:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/73\">",
"      Suntharalingam M, Moughan J, Coia LR, et al. The national practice for patients receiving radiation therapy for carcinoma of the esophagus: results of the 1996-1999 Patterns of Care Study. Int J Radiat Oncol Biol Phys 2003; 56:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/74\">",
"      Suntharalingam M, Moughan J, Coia LR, et al. Outcome results of the 1996-1999 patterns of care survey of the national practice for patients receiving radiation therapy for carcinoma of the esophagus. J Clin Oncol 2005; 23:2325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/75\">",
"      McKenzie S, Mailey B, Artinyan A, et al. Improved outcomes in the management of esophageal cancer with the addition of surgical resection to chemoradiation therapy. Ann Surg Oncol 2011; 18:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/76\">",
"      al-Sarraf M, Martz K, Herskovic A, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997; 15:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/77\">",
"      Crehange G, Maingon P, Peignaux K, et al. Phase III trial of protracted compared with split-course chemoradiation for esophageal carcinoma: Federation Francophone de Cancerologie Digestive 9102. J Clin Oncol 2007; 25:4895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/78\">",
"      Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 359:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/79\">",
"      Tougeron D, Scott&eacute; M, Hamidou H, et al. Definitive chemoradiotherapy in patients with esophageal adenocarcinoma: an alternative to surgery? J Surg Oncol 2012; 105:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/80\">",
"      Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23:2310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/81\">",
"      Bedenne L, Michel P, Bouch&eacute; O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007; 25:1160.",
"     </a>",
"    </li>",
"    <li>",
"     Stahl M, Wilke H, Lehmann N, et al. Long-term results of a phgase III study investigating chemoradiation with and without surgery in locally advanced squamous cell carcinoma (LA-SCC) of the esophagus (abstract). J Clin Oncol 2008; 26:220s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/83\">",
"      Bonnetain F, Bouch&eacute; O, Michel P, et al. A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer. Ann Oncol 2006; 17:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/84\">",
"      Welsh J, Settle SH, Amini A, et al. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer 2012; 118:2632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/85\">",
"      Monjazeb AM, Riedlinger G, Aklilu M, et al. Outcomes of patients with esophageal cancer staged with [&sup1;���F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection? J Clin Oncol 2010; 28:4714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/86\">",
"      Piessen G, Petyt G, Duhamel A, et al. Ineffectiveness of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Evaluation of Tumor Response After Completion of Neoadjuvant Chemoradiation in Esophageal Cancer. Ann Surg 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/87\">",
"      Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007; 8:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/88\">",
"      Ott K, Herrmann K, Lordick F, et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res 2008; 14:2012.",
"     </a>",
"    </li>",
"    <li>",
"     file://clinicaltrials.gov/ct2/show/NCT00316862.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/90\">",
"      Roth JA, Pass HI, Flanagan MM, et al. Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg 1988; 96:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/91\">",
"      Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/92\">",
"      Allum WH, Stenning SP, Bancewicz J, et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009; 27:5062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/93\">",
"      Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 2012; 19:68.",
"     </a>",
"    </li>",
"    <li>",
"     Schuhmacher C, Schlag P, Lordick F, et al. Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC phase III trial #40954) (Abstract #4510). J Clin Oncol 2009; 27:204s.",
"    </li>",
"    <li>",
"     Boige V, Pignon J, Saint-Aubert B, et al. Final results of a randomized trial comparing preoperative 5-fluorouracil/cisplatin to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial (abstract). J Clin Oncol 2007; 25:200s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/96\">",
"      Burmeister BH, Thomas JM, Burmeister EA, et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer 2011; 47:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/97\">",
"      Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003; 185:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/98\">",
"      Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007; 8:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/99\">",
"      Thames HD Jr, Peters LJ, Withers HR, Fletcher GH. Accelerated fractionation vs hyperfractionation: rationales for several treatments per day. Int J Radiat Oncol Biol Phys 1983; 9:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/100\">",
"      Withers HR. Biologic basis for altered fractionation schemes. Cancer 1985; 55:2086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/101\">",
"      Patel A, Wolfgang J, Niemierko A, et al. Implications of respiratory motion as measured by 4D CT for radiation treatment planning of esophageal tumors (abstract). Int J Radiat Oncol Biol Phys 2006; 66:S607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/102\">",
"      Leichman L, Herskovic A, Leichman CG, et al. Nonoperative therapy for squamous-cell cancer of the esophagus. J Clin Oncol 1987; 5:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/103\">",
"      Wright CD, Wain JC, Lynch TJ, et al. Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study. J Thorac Cardiovasc Surg 1997; 114:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/104\">",
"      Liu HH, Wang X, Dong L, et al. Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004; 58:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/105\">",
"      Murshed H, Liu HH, Liao Z, et al. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004; 58:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/106\">",
"      Schwarz M, Alber M, Lebesque JV, et al. Dose heterogeneity in the target volume and intensity-modulated radiotherapy to escalate the dose in the treatment of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2005; 62:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/107\">",
"      Minsky BD. Carcinoma of the esophagus. Part 2: Adjuvant therapy. Oncology (Williston Park) 1999; 13:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/108\">",
"      Kosugi S, Ichikawa H, Kanda T, et al. Clinicopathological characteristics and prognosis of patients with esophageal carcinoma invading adjacent structures found during esophagectomy. J Surg Oncol 2012; 105:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/109\">",
"      B&eacute;dard EL, Inculet RI, Malthaner RA, et al. The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma. Cancer 2001; 91:2423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/110\">",
"      Adelstein DJ, Rice TW, Rybicki LA, et al. Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction. J Thorac Oncol 2009; 4:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/111\">",
"      Tachibana M, Yoshimura H, Kinugasa S, et al. Postoperative chemotherapy vs chemoradiotherapy for thoracic esophageal cancer: a prospective randomized clinical trial. Eur J Surg Oncol 2003; 29:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/112\">",
"      Armanios M, Xu R, Forastiere AA, et al. Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: phase II trial (E8296) of the Eastern Cooperative Oncology Group. J Clin Oncol 2004; 22:4495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/113\">",
"      Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204. J Clin Oncol 2003; 21:4592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/31/39418/abstract/114\">",
"      Abate E, DeMeester SR, Zehetner J, et al. Recurrence after esophagectomy for adenocarcinoma: defining optimal follow-up intervals and testing. J Am Coll Surg 2010; 210:428.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2478 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-4E972C53F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_31_39418=[""].join("\n");
var outline_f38_31_39418=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SQUAMOUS CELL VERSUS ADENOCARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H964957130\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H486068\">",
"      THORACIC ESOPHAGUS TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Surgery alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RT alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Definitive chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RTOG 85-01",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Intergroup 0123",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Elderly patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Preoperative chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Concurrent chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H4965589\">",
"      - CROSS trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H4965660\">",
"      - CALGB 9781",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H4965704\">",
"      - Early stage disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Sequential chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Meta-analyses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H336671321\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H336671859\">",
"      - Intensification of preoperative therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Necessity for surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20504361\">",
"      Utility of postinduction therapy PET scans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Neoadjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Meta-analyses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Neoadjuvant chemotherapy versus chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3087792\">",
"      - Meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21960746\">",
"      Neoadjuvant chemotherapy versus postoperative chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Impact of preoperative treatment on local control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Technique for preoperative RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - 3D conformal RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Target volume",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Optimal dose and fractionation schedules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H484837\">",
"      Postoperative adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H484972\">",
"      - Chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H484979\">",
"      - Chemotherapy alone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H484986\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H493565\">",
"      POSTTREATMENT CANCER SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H493619\">",
"      CERVICAL ESOPHAGUS TUMORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8182417\">",
"      Thoracic esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8182762\">",
"      EGJ cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8182671\">",
"      Cervical esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2478\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2478|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/59/41907\" title=\"figure 1\">",
"      Anatomy of the stomach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/36/4678\" title=\"figure 2\">",
"      AJCC diagram of the esophageal anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2478|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/38/13934\" title=\"table 1\">",
"      TNM staging esoph SCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/24/4494\" title=\"table 2\">",
"      TNM staging esoph adenoCA including EGJ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/40/26252\" title=\"table 3\">",
"      Charlson risk index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/49/2846\" title=\"table 4\">",
"      Carboplatin and paclitaxel with RT for EGJ cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11882?source=related_link\">",
"      Adjuvant and neoadjuvant treatment of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/10/44202?source=related_link\">",
"      Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11850?source=related_link\">",
"      Clinical features, diagnosis, and staging of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7898?source=related_link\">",
"      Diagnosis and staging of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42006?source=related_link\">",
"      Endoscopic palliation of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32250?source=related_link\">",
"      Epidemiology, pathobiology, and clinical manifestations of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/41/6809?source=related_link\">",
"      Expandable stents in the treatment of esophageal obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30106?source=related_link\">",
"      Management of locally advanced unresectable esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/60/20426?source=related_link\">",
"      Management of superficial esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/51/39738?source=related_link\">",
"      Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/12/8391?source=related_link\">",
"      Pathogenesis of Barrett's esophagus and its malignant transformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/17/9491?source=related_link\">",
"      Patient information: Esophageal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/30/34282?source=related_link\">",
"      Surgical oncologic principles for management of resectable esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29770?source=related_link\">",
"      The role of parenteral and enteral/oral nutritional support in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43378?source=related_link\">",
"      Treatment protocols for esophagogastric cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_31_39419="Renal changes with aging";
var content_f38_31_39419=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Renal changes with aging",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Anatomic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decrease in renal mass, mostly from cortex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased renal fat and fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sclerosis of cortical nephrons with longest loops of Henle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Functional",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased renal blood flow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Impaired vasodilation in response to dopamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased creatinine clearance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Impaired sodium excretion and conservation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased potassium excretion and conservation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased concentrating and diluting capacity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Impaired excretion of acid loads",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased serum renin and aldosterone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Altered intrarenal nitric oxide actions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased dependence on renal prostaglandins to maintain intrarenal perfusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased vitamin D activation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased vulnerability to dye, ischemia, or other insults",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Impaired recovery after insults",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Taffet GE. Physiology of aging. In: Geriatric Medicine: An Evidence-Based Approach, Cassel CK, Leipzig RM, Cohen HJ, et al (Eds), 4th ed, Springer, New York 2003.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_31_39419=[""].join("\n");
var outline_f38_31_39419=null;
var title_f38_31_39420="Evaluation for TB";
var content_f38_31_39420=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for the evaluation of pulmonary tuberculosis (TB) in adults in five clinical scenarios",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Patient and setting",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any patient with a cough of &ge;2-3 weeks' duration, with at least one additional symptom, including fever, night sweats, weight loss, or hemoptysis",
"       </td>",
"       <td>",
"        Chest radiograph: if suggestive of TB*, collect three sputum specimens for acid-fast bacilli (AFB) smear microscopy and culture. At least one specimen should also be tested using a nucleic acid amplification (NAA) test.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any patient at high risk for TB",
"        <sup>",
"         &bull;",
"        </sup>",
"        with an unexplained illness, including respiratory symptoms, of &ge;2-3 weeks' duration",
"       </td>",
"       <td>",
"        Chest radiograph: if suggestive of TB*, collect three sputum specimens for AFB smear microscopy and culture. At least one specimen should also be tested using an NAA test.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any patient with HIV infection and unexplained cough and fever",
"       </td>",
"       <td>",
"        Chest radiograph, and collect three sputum specimens for AFB smear microscopy and culture. At least one specimen should also be tested using an NAA test.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any patient at high risk for TB",
"        <sup>",
"         &bull;",
"        </sup>",
"        with a diagnosis of community-acquired pneumonia who has not improved after 7 days of treatment",
"       </td>",
"       <td>",
"        Chest radiograph, and collect three sputum specimens for AFB smear microscopy and culture. At least one specimen should also be tested using an NAA test.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any patient at high risk for TB",
"        <sup>",
"         &bull;",
"        </sup>",
"        with incidental findings on chest radiograph suggestive of TB even if symptoms are minimal or absent",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Review of previous chest radiographs if available, three sputum specimens for AFB smear microscopy and culture. At least one specimen should also be tested using an NAA test.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Infiltrates with or without cavitation in the upper lobes or the superior segments of the lower lobes.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Patients with one of the following characteristics: recent exposure to a person with a case of infectious TB; history of a positive test result for Mycobacterium tuberculosis; HIV infection; injection or noninjection drug use; foreign birth and immigration &le;5 years from a region in which incidence is high; residents and employees of high-risk congregate settings; membership in a medically underserved, low-income population; or a medical risk factor for TB (including diabetes mellitus, conditions requiring prolonged corticosteroid and other immunosuppressive therapy, chronic renal failure, certain hematological malignancies and carcinomas, weight &gt;10 percent below ideal body weight, silicosis, gastrectomy, or jejunoileal bypass).",
"      <br>",
"       &Delta; Chest radiograph performed for any reason, including targeted testing for latent TB infection and screening for TB disease.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, the Infectious Diseases Society of America. MMWR Recomm Rep 2005; 54(RR-12):1. Daley CL, Gotway MB, Jasmer RM. Radiographic manifestations of tuberculosis: a primer for clinicians. San Francisco, CA: Francis J Curry National Tuberculosis Center; 2003: 1-30, and Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep 2009; 58:7.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_31_39420=[""].join("\n");
var outline_f38_31_39420=null;
var title_f38_31_39421="Recurrence rates after MMS";
var content_f38_31_39421=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Local recurrence rates following Mohs micrographic surgery compared to standard excision",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Skin cancer",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mohs micrographic surgery (MMS)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Wide excision",
"       </td>",
"       <td class=\"subtitle1\">",
"        Follow-up period",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Basal cell carcinoma",
"        <sup>",
"         [1-3]",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         1.4 to 3.2 percent",
"        </p>",
"        <p>",
"         2.4 to 6.7 percent*",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         4.1 percent",
"        </p>",
"        <p>",
"         12.1 percent*",
"        </p>",
"       </td>",
"       <td>",
"        5 years",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Squamous cell carcinoma",
"        <sup>",
"         [4,5]",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         1.2 to 2.6 percent",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         5.9 percent",
"         <sup>",
"          &bull;&Delta;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        5.7 to 8.1 percent (literature review rate)",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"       <td>",
"        3.9 years (mean)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Dermatofibrosarcoma protuberans",
"        <sup>",
"         [7,8]",
"        </sup>",
"       </td>",
"       <td>",
"        0 to 6.6 percent",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        13.2 percent",
"       </td>",
"       <td>",
"        4.8 to 5.4 years",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Atypical fibroxanthoma",
"        <sup>",
"         [9,10]",
"        </sup>",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        8.7 to 12",
"        <sup>",
"         &sect;",
"        </sup>",
"        percent",
"       </td>",
"       <td>",
"        4.5 to 8.7 years (median)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Extramammary Paget's disease",
"        <sup>",
"         [11,12]",
"        </sup>",
"       </td>",
"       <td>",
"        8",
"        <sup>",
"         &yen;",
"        </sup>",
"        to 18.2 percent",
"       </td>",
"       <td>",
"        22",
"        <sup>",
"         &yen;",
"        </sup>",
"        to 36.4 percent",
"       </td>",
"       <td>",
"        62.7 months (mean)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Sebaceous carcinoma",
"        <sup>",
"         [13,14]",
"        </sup>",
"       </td>",
"       <td>",
"        11.1 to 12",
"        <sup>",
"         ������",
"        </sup>",
"        percent",
"       </td>",
"       <td>",
"        30 percent",
"       </td>",
"       <td>",
"        37 months (mean)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Microcystic adnexal carcinoma",
"        <sup>",
"         [15,16]",
"        </sup>",
"       </td>",
"       <td>",
"        0",
"        <sup>",
"         ������",
"        </sup>",
"        to 5 percent",
"       </td>",
"       <td>",
"        50 percent",
"       </td>",
"       <td>",
"        5 years; only 13 cases",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Recurrent facial tumors.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      5 years.",
"      <br>",
"       &Delta; Recurrent tumor.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        Based on a literature review.",
"        <br>",
"         &sect; 73.6 m.",
"         <br>",
"          &yen; 24 m for MMS and 65 m for excision.",
"          <br>",
"           ������ 3.1 years (literature review rate).",
"           <br>",
"            ������ Mean.",
"            <br/>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Smeets NW, Krekels GA, Ostertag JU, et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: Randomised controlled trial. Lancet 2004; 364:1766.",
"       </li>",
"       <li>",
"        Leibovitch I, Huilgol SC, Selva D, et al. Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up. J Am Acad Dermatol 2005; 53:452.",
"       </li>",
"       <li>",
"        Mosterd K, Krekels GA, Nieman FH, et al. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face:&nbsp;A prospective randomised controlled trial with 5-years' follow-up. Lancet Oncol 2008; 9:1149.",
"       </li>",
"       <li>",
"        Leibovitch I, Huilgol SC, Selva D, et al. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I. Experience over 10 years. J Am Acad Dermatol 2005; 53:253.",
"       </li>",
"       <li>",
"        Pugliano-Mauro M, Goldman G. Mohs surgery is effective for high-risk cutaneous squamous cell carcinoma. Dermatol Surg 2010; 36:1544.",
"       </li>",
"       <li>",
"        Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992; 26:976.",
"       </li>",
"       <li>",
"        Snow SN, Gordon EM, Larson PO, et al. Dermatofibrosarcoma protuberans:&nbsp;A report on 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature. Cancer 2004; 101:28.",
"       </li>",
"       <li>",
"        Paradisi A, Abeni D, Rusciani A, et al. Dermatofibrosarcoma protuberans: Wide local excision vs. Mohs micrographic surgery. Cancer Treat Rev 2008; 34:728.",
"       </li>",
"       <li>",
"        Ang GC, Roenigk RK, Otley CC, et al. More than 2 decades of treating atypical fibroxanthoma at mayo clinic: What have we learned from 91 patients? Dermatol Surg 2009; 35:765.",
"       </li>",
"       <li>",
"        Davis JL, Randle HW, Zalla MJ, et al. A comparison of Mohs micrographic surgery and wide excision for the treatment of atypical fibroxanthoma. Dermatol Surg 1997; 23:105.",
"       </li>",
"       <li>",
"        Lee KY, Roh MR, Chung WG, Chung KY. Comparison of Mohs micrographic surgery and wide excision for extramammary Paget's Disease: Korean experience. Dermatol Surg 2009; 35:34.",
"       </li>",
"       <li>",
"        O'Connor WJ, Lim KK, Zalla MJ, et al. Comparison of mohs micrographic surgery and wide excision for extramammary Paget's disease. Dermatol Surg 2003; 29:723.",
"       </li>",
"       <li>",
"        Snow SN, Larson PO, Lucarelli MJ, et al. Sebaceous carcinoma of the eyelids treated by mohs micrographic surgery: Report of nine cases with review of the literature. Dermatol Surg 2002; 28:623.",
"       </li>",
"       <li>",
"        Spencer JM, Nossa R, Tse DT, Sequeira M. Sebaceous carcinoma of the eyelid treated with Mohs micrographic surgery. J Am Acad Dermatol 2001; 44:1004.",
"       </li>",
"       <li>",
"        Leibovitch I, Huilgol SC, Selva D, et al. Microcystic adnexal carcinoma: Treatment with Mohs micrographic surgery. J Am Acad Dermatol 2005; 52:295.",
"       </li>",
"       <li>",
"        Snow S, Madjar DD, Hardy S, et al. Microcystic adnexal carcinoma: Report of 13 cases and review of the literature. Dermatol Surg 2001; 27:401.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_31_39421=[""].join("\n");
var outline_f38_31_39421=null;
var title_f38_31_39422="Distribution of live births and infant deaths by gestational age";
var content_f38_31_39422=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 619px\">",
"   <div class=\"ttl\">",
"    Distribution of live births and infant deaths by gestational age in 2000 and 2007 in the United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 599px; height: 501px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Matthews TJ, MacDorman MF. Infant mortality statistics from the 2007 period linked birth/infant death data set. Natl Vital Stat Rep 2010; 59:6. Available at:",
"     <a href=\"file://www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59_06.pdf\" target=\"_blank\">",
"      file://www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59_06.pdf",
"     </a>",
"     (Accessed September 13, 2011).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_31_39422=[""].join("\n");
var outline_f38_31_39422=null;
var title_f38_31_39423="Ovarian steroid biosynthesis";
var content_f38_31_39423=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 494px\">",
"   <div class=\"ttl\">",
"    Ovarian steroid biosynthetic pathways",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 474px; height: 457px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Outline of the organization of the major steroid biosynthetic pathways in the small antral follicle of the ovary, depicted according to the two-gonadotropin, two-cell model of ovarian steroidogenesis. LH stimulates androgen formation within theca cells via the steroidogenic pathway common to the gonads and adrenal glands. FSH regulates estradiol biosynthesis from androgen by granulosa cells. Long-loop negative feedback of estradiol on gonadotropin secretion does not suppress LH at follicular phase levels of estradiol, nor do modest elevations of androgen suppress LH. Androgen formation in response to LH appears to be modulated by intraovarian feedback, mainly at the levels of 17-hydroxylase and 17, 20-lyase, both of which are activities of cytochrome P450c17. The quantitative importance of androstenedione formation from 17-hydroxyprogesterone (grey arrow) in the intact follicle is unknown. Androgens and estradiol inhibit (minus signs) and inhibin, insulin, and insulin-like growth factors (IGF) stimulate (plus signs) 17-hydroxylase and 17, 20-lyase activities. The steroidogenic enzymes appear in red.",
"    <div class=\"footnotes\">",
"     StAR: steroidogenic acute regulatory protein; scc: side chain cleavage; 3&beta;: &Delta; 5-isomerase-3&beta;-hydroxysteroid dehydrogenase; 17&beta;-HSD: 17&beta;-hydroxysteroid dehydrogenase types 1 and 5; 5&alpha;-R: 5&alpha;-reductase.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rosenfield RL. Ovarian and adrenal function in polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999; 28:265. Copyright &copy; 1999 WB Saunders.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_31_39423=[""].join("\n");
var outline_f38_31_39423=null;
